Stockwinners Market Radar for June 07, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:36 EDT Chico's says continuing conversations with shareholders, including Barington - Following today's letter from Barington Capital to Chico's management, the company states: "FAS has ongoing conversations with its shareholders, including Barington, to discuss the Company's strategy and operating plans and appreciates the input it receives. The company is making tremendous progress in its turnaround strategy to become a digital-first, customer-led company. This work, which commenced in the third quarter of 2019, was showing significant traction prior to the pandemic. In addition, actions taken over the last 18 months to reduce costs and strengthen the company's balance sheet provide a strong financial foundation to invest and grow for the foreseeable future. Chico's FAS looks forward to sharing more about the company's progress on its first quarter 2021 results tomorrow. We look forward to continuing to engage with all of our shareholders, including Barington, about this work and the execution of our transformation strategy. We are committed to taking all appropriate actions to improve performance and drive shareholder value."

18:11 EDT Mirati Therapeutics gets FDA Orphan Drug Designation in NSCLC treatment - Mirati Therapeutics announced it has received FDA Orphan Drug Designation for small molecule inhibitor of KRAS G12C mutant protein in treatment for KRAS G12C positive non-small cell lung cancer. Reference Link

18:03 EDT Dada Nexus announces up to $150M share buyback program

17:46 EDT Eversource VP Butler sells $985,920 in company shares - Eversource VP Gregory Butler disclosed that he had sold 12,000 shares of company stock for $82.16 per share on June 4 for a total transaction amount of $985,920.

17:30 EDT Stitch Fix says momentum will continue in Q4 - Says pleased with outperformance in Q3. Says shipped over 50M Fixes to date. Says continues to expand availability of Fix Preview. Says scaling advertising efforts in 2022. Says seeing tremendous momentum with private label. Comments taken from Q3 earnings conference call.

17:29 EDT Cyclerion Therapeutics CEO buys 302K shares of common stock - In a regulatory filing, Cyclerion Therapeutics disclosed that its CEO Peter Hecht bought 823K shares of common stock on June 3rd in a total transaction size of $2.7M, boosting his stake by about 67%. Shares of Cyclerion Therapeutics are up over 4% at $3.28 after-hours following the disclosed transaction.

17:22 EDT Summit Hotel Properties JV to acquire 110-guestroom Residence Inn for $33M - Summit Hotel Properties (INN) announced that it has entered into a definitive agreement to acquire the 110-guestroom Residence Inn by Marriott (MAR) Steamboat Springs for $33M through its joint venture, or JV, with GIC. Opened in December 2020, the newly built Residence Inn by Marriott Steamboat Springs is located close to the base of Mount Werner and Gondola Square, biking and hiking trails, downtown Steamboat Springs, restaurants, shopping and other attractions. The company expects to fund its 51% interest in the joint venture acquisition using approximately $17M of cash on-hand. After completion of the transaction, the company expects to have over $425M of total liquidity and over $150M of current investment capacity permitted under recent credit facility amendments to pursue future investment opportunities. The transaction is expected to be completed late in Q2 or early in Q3 and remains subject to customary closing conditions.

17:18 EDT Nike COO sells 14.3K shares of common stock - In a regulatory filing, Nike disclosed that its COO Andrew Campion sold 14.3K shares of common stock on June 3rd in a total transaction size of $1.90M, reducing his stake by about 12%.

17:15 EDT L Brands founder Leslie Wexner sells 5M shares of common stock - In a regulatory filing, L Brands disclosed that its founder Leslie Wexner sold 5M shares of common stock on June 3rd in a total transaction size of $326.5M, reducing his stake by about 24%.

17:09 EDT Afya sells Crescera stake to Bertelsmann - Afya Limited announced that it was notified by Crescera Educacional II Fundo de Investimento em Participacoes Multiestrategia, or "Crescera Educacional", of the sale of the entirety of its 23,074,134 Class B common shares of Afya to an affiliate of Bertelsmann SE& Co. KGaA, or "Bertelsmann." Since Afya's inception, Bertelsmann has indirectly held a stake in Afya through its investment in Crescera Educacional. In addition, Bertelsmann has had Daulins Emilio, the Managing Director at Bertelsmann Brazil Investments and Head of the Bertelsmann Corporate Center in Brazil, as representative on Afya's board since 2019. According to Afya's articles of association and shareholders agreement between the Esteves family and Crescera Educacional, Bertelsmann has the right to acquire Crescera Educacional's Class B common shares and accede to the shareholders' agreement. Upon consummation of the acquisition, Bertelsmann is expected to have the right to appoint the three members of Afya's board of directors currently appointed by Crescera Educacional. The transaction is subject to anti-trust approval and customary closing conditions.

17:00 EDT Bitcoin price falls to 1-week low below $34,500

16:39 EDT Conn's director Shein sells 6,000 shares of company stock - Conn's director Oded Shein disclosed ina filing that he had sold 6,000 shares of company stock at $30.06 per share on June 4 for a total transaction value of $180,360.

16:36 EDT Air Lease delivers one new Airbus A350-900 aircraft to World2Fly - Air Lease "announced the delivery of one new Airbus A350-900 aircraft, featuring Rolls-Royce Trent XWB engines, on long-term lease to World2Fly. This aircraft is the first of two new A350-900 aircraft confirmed to deliver to the airline from ALC's order book with Airbus."

16:35 EDT Enbridge sells 38.9% Noverco stake to Trencap for $1.14B in cash - Enbridge announced that a subsidiary of Enbridge has entered into a definitive agreement to sell its 38.9% non-operating minority ownership interest in Noverco Inc. to Trencap L.P. for $1.14B in cash, net of Noverco non-recourse debt assumed by Trencap L.P. This represents a valuation of approximately 29x reported 2020 GAAP earnings of $39M. Closing of the transaction is expected to occur by early 2022 and is subject to the receipt of regulatory approvals and customary closing conditions. Sale proceeds will initially be used to repay short term debt, and on this conservative basis the transaction is expected to be neutral to distributable cash flow per share. Noverco is currently owned 38.9% by Enbridge and 61.1% by Trencap L.P., a consortium lead by Caisse de depot et placement du Quebec. Noverco indirectly owns Energir, L.P. which is a Quebec-based business with interests primarily in gas distribution and power distribution in Quebec and Vermont.

16:32 EDT Merck's MSD Animal Health to acquire assets of LIC Automation, no terms - MSD Animal Health, a division of Merck & Co., announced its intention to acquire the assets of LIC Automation from New Zealand-based, farmer-owned cooperative Livestock Improvement Corporation. LICA is a leader in automation and technology for the dairy industry. Specific terms of the agreement were not disclosed.

16:32 EDT Urstadt Biddle increases quarterly dividend to 23c per share - At their regular meeting on Friday, the Board of Directors of Urstadt Biddle Properties declared quarterly dividends on the Company's Class A Common Stock and Common Stock. The dividends were declared in the amounts of 23c for each share of Class A Common Stock and 20.7c for each share of Common Stock. The dividends are payable July 16 to stockholders of record on July 2. See the Company's earnings press release, issued June 7, for a more detailed discussion of these increased dividends. The dividends represent the 206th consecutive quarterly dividend on common shares declared since the Company began operating in 1969. The Board of Directors also declared the regular quarterly dividends on the Company's Series H Preferred Stock and Series K Preferred Stock. The dividends were declared in the amount of $0.390625 for each share of Series H Preferred Stock and $0.3672 for each share of the Series K Preferred Stock. The dividends are payable July 30, 2021 to stockholders of record on July 16.

16:31 EDT PLBY Group falls about 9% to $47.56 after equity offering

16:28 EDT Gladstone Land acquires 639 gross acres of farmland in California for $25.4M - Gladstone Land announced that it has acquired 639 gross acres of farmland, including 617 planted acres of almonds, located in Kern County, California, and the option to purchase 20,330 acre-feet of stored water located within the Semitropic Water Storage District water bank for a total of approximately $25.4M. The company intends to immediately exercise its option to purchase the stored water. In connection with the acquisition, Gladstone Land entered into a 10-year, triple-net lease agreement for the farmland. This is the first closing of a three-part acquisition that is expected to result in total consideration of approximately $81.7M. The second and third closings are both currently scheduled to occur later this year.

16:27 EDT Marvell jumps over 2% to $49.32 after Q1 earnings beat

16:25 EDT Yellow Corp reports May shipments per workday 8.3% vs, 21.4% in April - Yellow Corporation reported certain operating metrics for the first two months of second quarter 2021. For Yellow less-than-truckload, the percent change 2021 from 2020:

16:23 EDT Gladstone Commercial appoints Gary Gerson as CFO - Gladstone Commercial (GOOD) announced that Gary Gerson has been appointed CFO, effective June 4. Gerson has served as Gladstone Commercial's interim CFO since March 26. Prior to joining the company, from 2013 to 2020, Gerson served as CFO of Spotted Hawk Development, an Apollo Investment (AINV) portfolio company.

16:19 EDT Coupa Software drops 5% to $223.97 after reporting Q1 results, FY22 guidance

16:18 EDT Pebblebrook Hotel Trust sees positive adjusted EBITDAre in Q2 - Additionally, the company announced that it executed a contract to sell its leasehold interest in The Roger New York for $19 million to an unaffiliated third party. The sale is subject to normal closing conditions, and the Company offers no assurances that this sale will be completed on these terms, or at all.

16:17 EDT Curtiss-Wright awarded contract for up to $70M to upgrade U.S. Navy helicopters - Curtiss-Wright (CW) announced that it was awarded a contract by Lockheed Martin (LMT) to provide its Modular Open System Approach computers and video processing modules to upgrade the Mission Computer and Flight Management Computer on the U.S. Navy's fleet of Sikorsky MH-60R/S Seahawk helicopters. The initial contract is valued at $24M, with an estimated lifetime value of $70M. Under the contract, Curtiss-Wright is providing Lockheed Martin with rugged single board computers and video processing modules. The modules result from Curtiss-Wright's Modified COTS program, which enables system integrators to upgrade individual modules in their legacy systems without having to replace the entire system, significantly speeding delivery of advanced technology to the warfighter. Shipments began in December 2020.

16:15 EDT Federal Realty announces acquisition of four properties - Federal Realty Investment Trust has acquired Grossmont Shopping Center in greater San Diego, California and Chesterbrook Shopping Center in McLean, Virginia and has entered into a binding contract to acquire Camelback Colonnade and Hilton Village in the Phoenix Metro area. Federal will own an average 80% interest in the four assets which total 1.75M square feet on 125 acres of land at a gross value of $407M. The assets under binding contract are expected to close by the end of June and are subject to completion of standard closing conditions.

16:11 EDT Galapagos increases share capital through subscription right exercises - Galapagos increases share capital through subscription right exercises Mechelen, Belgium; 7 June CET; regulated information -- Galapagos announces a share capital increase arising from subscription right exercises. Galapagos issued 10,940 new ordinary shares on 7 June for a total capital increase of EUR325,279. Galapagos issued 10,940 new ordinary shares on 7 June 2021, for a total capital increase (including issuance premium) of EUR325,279. Pursuant to the subscription right exercise program of Galapagos' management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, one management board member exercised 5,000 subscription rights.

16:09 EDT Marvell CEO says 'We began fiscal 2022 on a strong note' - "We began fiscal 2022 on a strong note, with stand-alone Marvell revenue growing 17% year-over-year for the first quarter. The acquisition of Inphi increases and accelerates our growth opportunity in the data center, Marvell's largest end market by revenue," said Matt Murphy, Marvell's President and CEO. "Marvell's outlook for strong revenue growth in the second quarter highlights robust demand across all our key end markets. I have never felt stronger about our prospects and believe that we are at the beginning of a multi-year growth cycle."

16:07 EDT Qorvo announces Interoperability with Apple U1 chip for iPhone and Apple Watch - Qorvo (QRVO) announced the interoperability of its DW3000 family of products with the Apple (AAPL) U1 chip used in iPhone and Apple Watch models and the new Nearby Interaction protocol specification draft unveiled at the 2021 Worldwide Developers Conference. This compatibility will enable developers to easily evaluate new app experiences based on location, distance and direction relative to a U1-equipped iPhone or Apple Watch. The DW3000 is Qorvo's next-generation ultra-wideband (UWB) chipset family and is ramping into full production in four variants, along with several modules and beta development kits. Compliant with the IEEE 802.15.4z standard, Qorvo UWB hardware and software solutions are also developed in accordance with the FiRa consortium PHY and MAC specification. As a sponsor and board member of FiRa, Qorvo is dedicated to growing the UWB ecosystem, and applying its technology and application expertise to help define specifications that ensure interoperability between different end products to create a seamless experience for consumers. Global tech market advisory firm ABI Research forecasts there will be 300 million UWB device shipments in 2021. "Smartphones will see an increase in the integration of UWB, providing users with the ability to accurately locate other UWB-enabled devices, unlock doors or vehicles, and automatically wireless pay for products," said Stephanie Tomsett, Research Analyst at ABI Research. Eric Creviston, president of Qorvo Mobile Products, said, "We're proud to be supporting Apple interoperability with our broad portfolio of UWB solutions. We are seeing rapid adoption of UWB in a variety of mobile, automotive and IoT applications, where it delivers unrivaled location and secure communication capabilities. This is opening the door to new user experiences. Qorvo's UWB team has been at the forefront of this innovation for 10 years, enabling hundreds of customers to design breakthrough products and solutions across 40 different vertical markets."

16:02 EDT Ironwood names Thomas McCourt as permanent CEO, CFO Consylman to step down - The company states: "Ironwood Pharmaceuticals announced that the board named Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as permanent chief executive officer. Mr. McCourt has also been appointed to serve on Ironwood's Board. With the appointment of Mr. McCourt, the Board is now comprised of 11 directors. Ironwood also announced that Gina Consylman plans to step down as senior vice president andCFO, effective July 2, 2021, in order to pursue another leadership opportunity at a rare disease biotechnology company. Ms. Consylman's resignation is not due to any disagreement with Ironwood on any matter relating to the company's financial reporting. Ironwood plans to initiate a search for Ms. Consylman's permanent successor and intends to name an interim CFO if a permanent successor has not yet been appointed by the date of Ms. Consylman's departure."

16:01 EDT CDC says study shows mRNA vaccines cut infection risk by 91% in fully vaccinated - A new CDC study finds the mRNA COVID-19 vaccines authorized by the Food and Drug Administration - Pfizer (PFE)-BioNTech (BNTX) and Moderna (MRNA) - reduce the risk of infection by 91% for fully vaccinated people. The findings come from four weeks of additional data collected in CDC's HEROES-RECOVER study of health care workers, first responders, frontline workers, and other essential workers. These groups are more likely to be exposed to the virus that causes COVID-19 because of their occupations. Preliminary results from this study were first announced in March 2021. "This adds to the growing body of real-world evidence of their effectiveness. Importantly, this study also is among the first to show that mRNA vaccination benefits people who get COVID-19 despite being fully vaccinated or partially vaccinated," the CDC stated. Reference Link

15:46 EDT HOOKIPA Pharma trading halted, volatility trading pause

15:31 EDT PDS Biotechnology Corp trading halted, volatility trading pause

14:51 EDT Apple announces watchOS 8 - Apple previewed watchOS 8, with new features for the wearable operating system. The company said that "updates to the Wallet and Home apps extend Apple Watch as an increasingly useful tool for convenient access across the car and places users live, work, and visit." Apple added, "A reimagined Breathe app and new Tai Chi and Pilates workout types help users lead a fit and healthy life and support mental well-being, while a new Portraits watch face and enhancements to Messages and the Photos app make staying connected to loved ones even easier." A public beta will be available to watchOS users next month. watchOS 8 will be available this fall as a free software update for Apple Watch Series 3 or later paired with iPhone 6s or later, running iOS 15.

14:48 EDT Apple showcases new privacy features for iOS 15, iPadOS 15, macOS Monterey - Apple previewed new privacy protections in iOS 15, iPadOS 15, macOS Monterey, and watchOS 8, which help users better control and manage access to their data. "Privacy has been central to our work at Apple from the very beginning," said Craig Federighi, Apple's senior vice president of Software Engineering. "Every year, we push ourselves to develop new technology to help users take more control of their data and make informed decisions about whom they share it with. This year's updates include innovative features that give users deeper insights and more granular control than ever before." In the Mail app, Mail Privacy Protection stops senders from using invisible pixels to collect information about the user. The new feature helps users prevent senders from knowing when they open an email, and masks their IP address so it can't be linked to other online activity or used to determine their location. For a number of years, Intelligent Tracking Prevention has helped protect Safari users from unwanted tracking by using on-device machine learning to stop trackers while allowing websites to function normally. This year, Intelligent Tracking Prevention is getting even stronger by also hiding the user's IP address from trackers. This means they can't utilize the user's IP address as a unique identifier to connect their activity across websites and build a profile about them. With App Privacy Report, users can see how often each app has used the permission they've previously granted to access their location, photos, camera, microphone, and contacts during the past seven days. Users can check whether this makes sense to them, and take action by going to the app in Settings if it doesn't. Users can also find out with whom their data may be shared by seeing all the third-party domains an app is contacting. With on-device speech recognition, the audio of users' requests is processed right on their iPhone or iPad by default. For many requests, Siri processing is also moving on device, enabling requests to be processed without an internet connection, such as launching apps, setting timers and alarms, changing settings, or controlling music. In addition, Private Relay is a new internet privacy service that's built right into iCloud, allowing users to connect to and browse the web in a more secure and private way. When browsing with Safari, Private Relay ensures all traffic leaving a user's device is encrypted, so no one between the user and the website they are visiting can access and read it, not even Apple or the user's network provider. All the user's requests are then sent through two separate internet relays. The first assigns the user an anonymous IP address that maps to their region but not their actual location. The second decrypts the web address they want to visit and forwards them to their destination. This separation of information protects the user's privacy because no single entity can identify both who a user is and which sites they visit.

14:47 EDT Apple previews iPadOS 15 with new productivity features - Apple previewed iPadOS 15, with new features that it says "take advantage of the unique capabilities of iPad, helping users be more productive and taking the versatility of iPad even further." Apple added: "iPadOS 15 introduces a multitasking experience that is even more intuitive, making features like Split View and Slide Over easier to discover, easier to use, and more powerful. Notes goes systemwide with Quick Note, and offers new ways to collaborate and organize whether typing or writing with Apple Pencil(R). New widget layouts for the Home Screen and App Library offer simple ways to personalize the iPad experience and organize apps. Translate delivers new features for translating text and conversations, and users can now build apps for iPhone(R) and iPad, on iPad, with Swift Playgrounds. iPadOS 15 also includes new privacy controls in Siri(R), Mail, and more places across the system to further protect user information." The developer preview of iPadOS 15 is available to Apple Developer Program members starting today, and a public beta will be available to iPadOS users next month. New software features will be available this fall as a free software update for iPad mini 4 and later, iPad Air 2 and later, iPad 5th generation and later, and all iPad Pro models.

14:44 EDT Apple introduces Xcode Cloud for developers - Says Xcode Cloud makes it easier for development teams to work together. Says Xcode Cloud runs automated tests in parallel for every kind of Apple device and platform. Says providing access to limited beta of Xcode Cloud today. Says will be available to all developers next year.

14:39 EDT Apple introduces updated Safari on Mac with tab groups - Says bringing Shortcuts app to Mac. Says Safari getting updated design on Mac with new tab presentation and privacy options. Says users can share tab group in an email automatically. Says Tab groups sync to iPad automatically and to iPhone with tab bar button. Says web extensions coming to iPhone and iPad.

14:25 EDT Apple says Monterey to allow syncing between iOS devices and Mac computers - Says Monterey to allow syncing between iOS and Mac. Says iPad automatically recognizes cursor when set up right next to Mac computer with Monterey. Says can use trackpad on Macbook to control iPad when synced up via Monterey update.

14:21 EDT Apple allows Siri to work on third-party home devices - Says new Home Keys feature lets users tap iPhone, Apple Watch to unlock front door. Says now allowing HomePod Mini speaker to control Apple TV via Siri. Says will start selling HomePod Mini in Australia and Ireland. Says Siri requests can go directly to third-party devices in HomePod.

14:12 EDT Apple introduces watchOS 8 with new health features - Says watchOS 8 to include enhanced Breath app, with new "Reflect" feature. Says Watch now has Mindfulness app. Says Watch now features new workout types including Tai Chi and Pilates. Says watchOS 8 now comes with portrait mode watch face. Says photos app on watchOS 8 has been "completely redesigned."

14:01 EDT Alexion announces FDA approval of Ultomiris for adolescents, children in PNH - Alexion Pharmaceuticals announced the U.S. Food and Drug Administration has approved the expanded use of ULTOMIRIS to include children and adolescents with paroxysmal nocturnal hemoglobinuria. ULTOMIRIS, a long-acting C5 inhibitor that offers immediate, complete and sustained complement inhibition, is now the first and only FDA-approved medicine for children and adolescents with PNH, the company said in a statement. This approval is based on interim Phase 3 study results, which showed that ULTOMIRIS was effective in achieving complete C5 complement inhibition through 26 weeks in children and adolescents up to 18 years of age.

13:55 EDT Apple to add on device speech recognition to Siri - Says new email on iPad to hide IP address from tracking pixels and doesn't let marketers see if and when you open an email. Says Safari Intelligent Tracking Prevention now also hides IP addresses. Says adding on device speech recognition to Siri.

13:43 EDT Apple introduces iPadOS 15 - Says App Library feature coming to iPad. Says iPadOS 15 to include widgets on the homescreen, as well as a Files widget.

13:33 EDT Apple says Maps to include more topographical details - Apple says Maps update to come with more topographical details, including for landmarks. Says adding new road details to Maps to make turn lanes, medians, and bus lanes more visible on the app. Says adding improvements to transit directions in Maps app.

13:30 EDT Biogen jumps 49% to $427.33 following FDA approval of Aduhelm - After Biogen shares resumed trading the stock is up $141.19, or 49%, to $427.33.

13:30 EDT Biogen trading resumes

13:21 EDT Apple's FaceTime coming to Android, Windows through the web - Apple (AAPL) says FaceTime coming to Android (GOOG), Windows (MSFT) via the web. Says notifications now include photos for contacts. Says introducing Notification Summary, a collection of notifications ordered by priority. Says Notification Summary can be sent to users at a time of day of their choosing. Says new Focus feature that lets users set up modes for work, personal use that uses on-device AI to try to pre-guess what notifications users want.

13:15 EDT Apple unveils iOS 15 with improved FaceTime - Apple (AAPL) says aiming to make FaceTime calls "more lifelike." Says bringing spatial audio, voice isolation to FaceTime. Says SharePlay can let users listen together, watch together, and share screens in FaceTime calls. Says introducing "grid view" to FaceTime. Says SharePlay to let users stream shows in platforms like Disney+ (DIS) and HBO Max (T) and watch them together. Says SharePlay's screen sharing to allow users to watch each other play games or browse Zillow (Z). Comments taken from Worldwide Developers Conference Keynote.

13:08 EDT Biogen says value-based pacts in progress with Cigna, other payers for Aduhelm - Following today's U.S. Food and Drug Administration's accelerated approval of Aduhelm as "the first and only Alzheimer's disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain," Biogen (BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co. (ESALY), announced a range of programs intended to support access for all qualified patients, including traditionally underserved populations. "These initiatives aim to help patients and their families understand the disease, navigate the diagnostic journey, secure culturally competent care and afford treatment," the companies stated. Biogen and Eisai have established a program with Labcorp (LH) and Mayo Clinic Laboratories to help physicians and patients access cerebrospinal fluid, or CSF, diagnostic laboratory testing to aid in the diagnosis of Alzheimer's disease, the companies said. With the Veterans Health Administration, or VHA, Biogen is working to finalize a multi-year agreement in order to support access for veterans throughout the VHA system. Biogen has also entered into an initiative with CVS Health (CVS) focused on the importance of brain health, screening and disease education. As part of this effort, cognitive screenings will be available through CVS Health's Project Health, a longstanding health services program helping address care disparities for uninsured and underinsured Americans, particularly in racially and ethnically diverse communities.The program is scheduled to begin in September in the following cities: Atlanta, Boston/Providence, Charlotte, Charleston/Columbia, Chicago, Dallas/Fort Worth, Detroit, Houston, Jackson/Memphis, Los Angeles, Miami, New York City, Philadelphia, and Washington DC. The companies said they have been working closely with payers to prepare them for the launch of Aduhelm and support patient access. In that regard, Biogen and Cigna Corporation (CI), a global health service company, intend to enter into a value-based contract to "ensure that there is a streamlined path to access treatment for patients consistent with the population in which Aduhelm was studied," the company said. The parties will also be tracking performance towards certain outcome metrics for patients. Biogen and Eisai have committed to not increasing the price of Aduhelm for the next four years, the companies added.

13:06 EDT Ubisoft renames 'Rainbow Six Quarantine' to 'Rainbow Six Extraction' - Ubisoft announced that the next game in its "Tom Clancy's Rainbow Six" franchise will be called "Rainbow Six Extraction." The previous name for the game was "Rainbow Six Quarantine."

12:47 EDT Retractable Technologies approves repurchase of up to $10M of common stock - Retractable Technologies announced that its board of directors has approved the adoption of a repurchase plan for up to $10M of its common stock. Under the plan, open market purchases of Retractable's common stock may commence June 18, 2021 and may continue until June 18, 2022 at the latest. The board of directors has also approved payment to its Class B Convertible Preferred shareholders of all current dividends, dividends in arrears, as well as dividends still owed to shareholders who converted their preferred stock in the past. Thomas Shaw, President and CEO of Retractable, states, "Our management is embarking on purchasing the company's stock because - thanks to the dedication of our shareholders and continued efforts of our employees - the U.S. government has recognized as has the medical community that our technology provides a significant advantage in terms of eliminating waste of vital and costly medications and helps prevent the unnecessary spread of infectious diseases. Under these established circumstances, we believe that the company's stock is significantly undervalued."

12:16 EDT Georgia Power says Vogtle Unit 4 achieves initial energization - Southern Company's Georgia Power announced that plant equipment for Vogtle Unit 4 is now energized, or permanently powered, which is needed to perform all subsequent testing for the unit at the Vogtle 3 & 4 nuclear expansion project. With plant equipment previously running on temporary construction power, the achievement of initial energization marks another step towards system operations as Unit 4 continues to progress through its testing phase. Earlier this year, the project team started the integrated flush testing process on Unit 4, which pushes water through the permanent plant system piping that feeds into the reactor vessel and reactor coolant loops. Integrated flush represents a critical step as the process is key to helping ensure the safe startup of Unit 4 and initiated the start of extensive testing ahead for the unit's systems.

12:06 EDT Google Stadia to be available on Chromecast, Android TV devices on June 23 - Google said that the first version of its Stadia game streaming service on Chromecast with Google TV is launching on June 23. In addition, Google said users will be able to play Stadia on compatible Android TV OS devices on June 23. Reference Link

12:00 EDT Intercorp Financial Services falls -11.9% - Intercorp Financial Services is down -11.9%, or -$3.63 to $27.00.

12:00 EDT Frank's International falls -12.7% - Frank's International is down -12.7%, or -47c to $3.25.

12:00 EDT AMC Entertainment rises 17.7% - AMC Entertainment is up 17.7%, or $8.49 to $56.40.

11:36 EDT AbbVie says ibrutinib/venetoclax cohort met primary endpoint in CAPTIVATE study - AbbVie announced new data from the Phase 2 CAPTIVATE study investigating IMBRUVICA in combination with VENCLEXTA/VENCLYXTO, an all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination, for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma during an oral presentation at the virtual 2021 American Society of Clinical Oncology Annual Meeting. The ibrutinib and venetoclax cohort met its primary endpoint of complete response rate of 56% among patients without del, 70 years old or younger and with 27.9 months of follow up. This rate was higher than the 37% minimum meaningful rate study assumption. The CR rate was consistent across all patients in the study including high-risk CLL patient groups. Furthermore, 24-month progression free survival and overall survival were 95% and 98%, respectively. Ibrutinib plus venetoclax is an investigational fixed-duration combination. Patients received 3 cycles of ibrutinib lead-in followed by 12 cycles of ibrutinib + venetoclax. At 27.9 months median duration of follow-up in the fixed-duration cohort, complete response rate was 56% without del, and CR, including complete response with incomplete marrow recovery, was 55% in the overall study population and was consistent across high-risk subgroups. Undetectable minimal residual disease was achieved in 77% of patients in peripheral blood and 60% of patients in bone marrow. The most common grade 3/4 adverse effects were neutropenia, hypertension and neutrophil count decreased. AEs led to discontinuation of ibrutinib in 4% and venetoclax in 2% of patients. The safety profile of the combination was generally consistent with known AEs for each agent and no new safety signals were identified. This data builds on previously reported results from the Minimal Residual Disease cohort where undetectable uMRD was achieved in over two-thirds of patients with 12 cycles of ibrutinib plus venetoclax, and 30-month PFS rates were greater than or equal to95% irrespective of subsequent randomized treatment. CAPTIVATE data will also be presented at the European Hematology Association's congress taking place from June 9-17, 2021. Additionally, there are other ongoing company-sponsored and investigator-initiated trials exploring the potential of ibrutinib and venetoclax in combination for CLL treatment, including the Phase 3 GLOW study. Results from the ongoing GLOW study, assessing the ibrutinib plus venetoclax combination in comparison to chlorambucil plus obinutuzumab for first-line treatment of patients with CLL or SLL, will be presented at the upcoming EHA congress.

11:27 EDT Report claiming Pershing Square Tontine worth $30 worth read, Ackman says - A report by Empire Research saying Pershing Square Tontine Holdings (PSTH) should be a $30-plus stock is "worth a read," Pershing Square's Bill Ackman tweeted. Shares of Pershing Square Tontine are up 57c to $22.63 in morning trading. Reference Link

11:11 EDT FDA requiring Biogen to conduct post-approval clinical trial in Alzheimer's - The FDA said in its approval statement: "Additionally, FDA is requiring Biogen to conduct a post-approval clinical trial to verify the drug's clinical benefit. If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm. As an agency, we will also continue to work to foster drug development for this catastrophic disease."

11:08 EDT FDA approves Biogen Alzheimer's drug, says benefits outweigh risks - The FDA approved Biogen's (BIIB) Aduhelm to treat patients with Alzheimer's disease. "This approval is significant in many ways. Aduhelm is the first novel therapy approved for Alzheimer's disease since 2003. Perhaps more significantly, Aduhelm is the first treatment directed at the underlying pathophysiology of Alzheimer's disease, the presence of amyloid beta plaques in the brain. The clinical trials for Aduhelm were the first to show that a reduction in these plaques - a hallmark finding in the brain of patients with Alzheimer's - is expected to lead to a reduction in the clinical decline of this devastating form of dementia," the FDA said in a statement. It added, "We ultimately decided to use the Accelerated Approval pathway - a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer's disease outweighed the risks of the therapy." Shares of Biogen remain halted while Eli Lilly, who has an Alzheimer's disease drug in its pipeline, is up 4% to $210.78 following the news. Reference Link

11:03 EDT FDA approves Biogen's Aduhelm for Alzheimer's disease

10:45 EDT 22nd Century announces partnerships with plant breeders, Aurora Cannabis - 22nd Century Group (XXII) announced new initiatives to strengthen and maximize revenue opportunities in its hemp/cannabis franchise. Included in these developments is the announcement of strategic partnerships with two plant breeders in the northern and southern hemispheres providing the company with year-round growing capabilities, close partnership activities being conducted with Aurora Cannabis (ACB), and the establishment of a newly created Canadian subsidiary. These newest developments further support 22nd Century's plans for multiple avenues of hemp/cannabis revenue that will begin to be realized in late 2021. With its breeding partnerships in place, 22nd Century Group has now secured all key partnerships needed to maximize and support each of the five components in the upstream segment of the cannabinoid value chain including: plant profiling; plant biotechnology; commercial-scale plant breeding; plant cultivation; and ingredient extraction/purification. The company will provide details regarding the breeding strategic partnerships later this month and will present its go forth commercialization strategy for its hemp/cannabis franchise on its second quarter 2021 earnings call in early August. The company is actively pursuing multiple hemp/cannabis revenue streams targeted in 2021. 22nd Century and Aurora are working closely together to enforce their IP against infringing parties and are exploring collaborative commercial development opportunities. The company expects licensing and revenue from the IP shared with Aurora to commence in the second half of 2021. 22nd Century's Canadian subsidiary, 22nd Century Canada, Inc., incorporated in April 2021, will serve as a base for the company's expanded activities in tobacco, hemp/cannabis and its yet-to-be announced third franchise.

10:37 EDT Minerco Resources CEO says will 'fully cooperate with SEC' in timely manner - Minerco announced that on May 26, 2021, the Company was notified by the SEC that it had ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed Company is suspended for the period from 9:30 a.m. EDT on May 27, 2021, through 11:59 p.m. EDT on June 10, 2021. Julius Jenge, CEO of Minerco, Inc. said: "The Company has hired SEC counsel and will fully cooperate with the SEC in a timely manner. We will provide additional information and updates as permitted, to our shareholders and the markets as the matter develops." The Order of Suspension of Trading stated that: " It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of Minerco, formerly a Nevada company, because of questions and concerns regarding the adequacy and accuracy of information about the Company in the marketplace and unusual and unexplained activity affecting the market for its securities. These include questions and concerns about the status of its corporate organization, its ownership, the accuracy and completeness of its public statements to investors about its activities, inconsistencies between its statements on social media and in its press releases as compared to its financial disclosures on www.OTCMarkets.com, and the possibility of manipulation of the market for its securities. As of May 21, 2021, the Company's common stock was quoted and traded on OTC Link whose parent company is OTC Markets Group Inc., under the symbol MINE. As of May 21, 2021, the Company's common stock, had seven market makers, and was eligible for the "piggyback" exception of Exchange Act Rule 15c2- 11(f)(3) under the Securities and Exchange Act of 1934. The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed Company."

10:33 EDT Atara Biotherapeutics presents tab-cel long-term overall survival data - Atara Biotherapeutics announced a combined long-term overall survival analysis from three clinical studies of tabelecleucel in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease after solid organ transplantation. The results are featured in an oral plenary presentation at the American Transplant Congress, taking place June 4-9, 2021. Combined objective response rate and OS data across two SOT subgroups - patients relapsed or refractory to rituximab monotherapy and patients R/R to rituximab + chemotherapy - showed one- and two-year OS for patients achieving either complete response or those achieving partial response. Data presented at ATC 2021 confirm benefit of tab-cel in SOT PTLD and show similar one- and two-year probability of OS irrespective of patients achieving CR or PR . Treatment response and OS data were assessed from two completed single-arm, Phase 2 studies and the multi-center expanded access study. "Patients who have received a solid organ transplant such as a new kidney, lung, heart or liver and go on to develop EBV+ PTLD that is relapsed or refractory to rituximab monotherapy or R-chemotherapy face a poor prognosis, with median survival of only about three months," said Jakob Dupont, M.D., Head of Global Research & Development at Atara. "There is a significant unmet need in these patients for whom there are no approved therapies, let alone therapies specifically designed to treat EBV+ PTLD. Combined data from across three clinical studies in SOT recipients with relapsed or refractory disease demonstrated similar long-term survival benefit in those who had either partial or complete response to treatment. These data indicate that tab-cel may help address an urgent unmet need in these patients with high rates of mortality." All SOT recipients with EBV+ PTLD R/R to rituximab as monotherapy or combined with chemotherapy were treated with tabelecleucel, receiving a median of 2.0 cycles. Atara has previously shown benefit in patients with EBV+ PTLD after SOT who responded to tab-cel, including up to 100 percent two-year survival rates1,2. Data presented at EBMT 2021 demonstrated similar results in terms of overall survival in EBV+ PTLD patients who received tab-cel following hematopoietic cell transplantation. Tab-cel was well-tolerated in this immunocompromised population with high disease burden and multiple comorbidities. Notably, there was no emerging safety concern and no instances of tumor flare reaction, infusion-related reactions, graft versus host disease, cytokine release syndrome, neurotoxicity or organ rejection reported in these patients.

10:25 EDT Dave to become publicly-traded via VPC Impact Acquisition Holdings III merger - Dave and VPC Impact Acquisition Holdings III, a special purpose acquisition company sponsored by Victory Park Capital, announced that they have entered into a definitive agreement for a business combination that will result in Dave becoming a publicly traded company listed under the ticker symbol "DAVE," with an expected pro forma, fully-diluted equity value of approximately $4B, assuming no redemptions. Launched in 2017 as an app to help Americans avoid billions of dollars in overdraft fees charged by traditional banks, Dave is now a financial platform helping 10M customers with banking, financial insights, overdraft protection, building credit and finding side gigs. Dave aims to help foster the financial health of its members while also giving back to the community, having pledged over 13 million meals to Feeding America since launch. To date, Dave estimates that it has helped customers avoid nearly $1B in overdraft fees through its flagship feature, ExtraCash, and earn over $200M in income through its gig-economy job board, Side Hustle. In December 2020, the company launched Dave Banking, a spending account and debit card with no monthly fees, which has already accumulated more than 1.3M members. VPC has been a longstanding investor in Dave, most recently providing a $100M credit facility to the company in January 2021. VPCC completed its initial public offering in March 2021. Dave has been backed by world-class investors including Norwest, Section 32, Capital One, Mark Cuban Companies, The Kraft Group, SV Angel and The Chernin Group. The company's board of directors includes Jason Wilk; Dan Preston, CEO of Metromile; Bill Maris, Google Ventures Founder; Parker Barrile, Partner at Norwest Venture Partners; and Mark Cuban. Upon completion of the transaction, the combined company is expected to have a fully-diluted equity value on a pro forma basis of approximately $4 billion, assuming no redemptions. It is expected to result in over $375 million of cash on the combined company's balance sheet, reflecting a contribution of up to $254M of cash held in VPCC's trust account and a $210M concurrent private placement led by Tiger Global Management with additional participation from Wellington Management and Corbin Capital Partners. The proposed business combination has been unanimously approved by the Boards of Directors of Dave and VPCC, and is subject to approval by VPCC's stockholders, regulatory approvals and other customary closing conditions. The business combination is expected to close late in the third quarter or in the fourth quarter of 2021.

10:20 EDT SEC says monitoring 'volatility in certain stocks' after AMC rally

10:19 EDT MDC Partners, Stagwell urge shareholders to approve combination - Stagwell Media, released comments by Mark Penn, the CEO and Chairman of MDC Partners and the Managing Partner of Stagwell, urging shareholders to approve the Stagwell-MDC combination. Penn said, " It's time for MDCA shareholders to unite to get the Stagwell-MDC combination across the finish line. Nearly 10,000 jobs and careers have hung in the balance for almost a year and now is the time for shareholders to come together to approve this value-creating and much-needed combination. Today, Stagwell has taken two major actions: Announced our intended Board of Directors nominees and agreed to have a majority independent Board. We have pledged to have an independent Board of Directors and nominated stellar new Directors including Rodney Slater, former Secretary of Transportation; Paul Richardson, the former CFO of WPP; and Brandt Vaughn, COO/CIO of the Ballmer Group. This is a high-powered Board for a new, high-powered company. They would serve in addition to members from the existing Board. Indicated a willingness to give up 20 million shares Stagwell would have received under the terms of the original deal struck between Stagwell and MDC's Special Committee in December if the Special Committee can obtain unquestioned and broad support from MDCA shareholders in the near term. This would in effect move the deal, we believe, to nearly a 30/70 split from the originally proposed 18/82 split and the 26/74 split that was negotiated by the Special Committee. The value of these 20 million shares, as of the close on Friday, was $100 million dollars. Remember that on the day we submitted our original proposal to combine with MDCA last June, the entire equity value of MDCA was hovering around $100 million dollars. When it comes to governance, I hope all shareholders will recognize the quality of these new Directors and the role they can play in helping to steer this new company to greater heights. When it comes to deal economics, I hope shareholders will see our proposed "bump" as a significant concession and look to the mutual success we can all have if we close this deal now. We have made this most recent economic proposal despite a strong defense by the Special Committee of the deal we struck (link: https://bit.ly/3ikLJxB) and our own belief that the deal agreed in December is fair and reasonable as it stands. However, we wanted to indicate our willingness to go the extra mile on behalf of the future of the company with this potential revision. We are making this one-time, best and final offer in order to drive this transaction to a smooth approval and quick closing. It's deal or no deal time. The shareholder benefits of this deal have been widely recognized in the marketplace, with the increase in stock value from $1.15 per share the day before Stagwell announced its interest in a combination to approximately $5 per share now. Shareholders are benefiting already from this transaction and I want to now secure those benefits for shareholders by getting the deal to the finish line. My vision is to create a growing platform to transform marketing by bringing together the best in creativity with the best digital expertise in a scaled platform. This combination, I firmly believe, will lead to a better balance sheet, greater shareholder liquidity, $30 million dollars in annual run-rate synergies, meaningful scale, and a chance for sustained, profitable growth. We anticipate a potential refinancing alone supported by the new balance sheet of the combined company can save an estimated $20 million a year. All of this should spell significant value creation for all stakeholders."

10:10 EDT Rexford Industrial announces $76.3M transaction activity - Rexford Industrial Realty announced the acquisition of five industrial properties comprising 79,305 square feet of improvements on 18.8 acres of land for an aggregate purchase price of $68.1M. The company also announced the disposition of one industrial property for $8.2M. The acquisitions were funded using a combination of cash-on-hand and 1031 disposition proceeds.

10:06 EDT Exfo announces going-private transaction by founder Germain Lamonde - EXFO announced that it has entered into an arrangement agreement pursuant to which 11172239 Canada, a corporation controlled by Germain Lamonde, EXFO's founder and majority shareholder, will acquire all of the issued and outstanding subordinate voting shares of the Corporation, except for 3,672,474 Subordinate Voting Shares already controlled, directly or indirectly, by Germain Lamonde. As of June 7, 2021, Germain Lamonde controls, directly or indirectly, the Excluded Shares and 31,643,000 multiple voting shares of the Corporation, representing 14.22% of the issued and outstanding Subordinate Voting Shares, and 100% of the issued and outstanding Multiple Voting Shares and, respectively, representing collectively 61.46% of the issued and outstanding shares of the Corporation and 93.53% of the voting rights attached to all the issued and outstanding Shares. Holders of Subordinate Voting Shares will receive US $6.00 per Subordinate Voting Share in cash, representing a 62% premium to the closing price per Subordinate Voting Share on the Nasdaq Global Select Market on June 4, 2021, and a 63% premium to the 20-day volume-weighted average trading price for the Subordinate Voting Shares on the Nasdaq Global Select Market for the period ending on June 4, 2021, the last trading day prior to the date of this announcement. The board of directors of EXFO, with Germain Lamonde and Philippe Morin having recused themselves from the meeting, acting on the unanimous recommendation of the special committee of the Board of Directors comprised entirely of independent directors, unanimously approved the Arrangement and unanimously recommends that shareholders vote in favour of the Arrangement at a special meeting of shareholders held to approve the Arrangement. In connection with the Arrangement, all the directors and certain officers have entered into support and voting agreements pursuant to which they have agreed, subject to the terms thereof, to vote all of their Subordinate Voting Shares in favour of the Arrangement Resolution. Upon completion of the proposed transaction, Germain Lamonde will directly or indirectly beneficially own or control all of the issued and outstanding Subordinate Voting Shares and Multiple Voting Shares.

10:06 EDT GAC Media acquires Great American Country from Discovery - GAC Media, LLC, a newly-formed group of US-based investors announced that it has acquired the Great American Country Network from Discovery, Inc. GAC's format includes lifestyle programming and is available in approximately 40 million television households. Contemporaneous with its acquisition of GAC, GAC Media has also acquired RIDE TV, a 24-hour, high-definition television network dedicated to showcasing equestrian sports, culture and lifestyle. Deal terms for GAC and the RIDE TV acquisitions, both of which have closed, were not disclosed.

10:02 EDT Kimberly-Clark partners with RWDC for sustainable alternatives to plastics - Kimberly-Clark announced a partnership with the biotech company RWDC Industries to advance sustainable technology for consumer products that provides much-needed solutions to the world's single-use plastics problem. The collaboration brings together Kimberly-Clark's experience in nonwoven technologies and resin development with RDWC's biopolymer solutions. The partnership will provide Kimberly-Clark with RWDC's polyhydroxyalkanoates source material, Solon, to develop additional products that are marine degradable. This new source material for Kimberly-Clark's personal care products is one of the strategies the company is developing as part of its recently announced sustainability ambitions for 2030 that include a transition away from traditional fossil fuel-based plastics toward more renewable and regenerative materials. The company is working to launch products featuring this innovation over the next five years, focusing first on product categories that address global demand for more sustainable products.

10:00 EDT Intercorp Financial Services falls -8.1% - Intercorp Financial Services is down -8.1%, or -$2.49 to $28.14.

10:00 EDT Citius Pharmaceuticals set to join Russell 2000 Index - Citius Pharmaceuticals announced that it is set to be added to the Russell 2000 Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28.

10:00 EDT AMC Entertainment rises 14.0% - AMC Entertainment is up 14.0%, or $6.69 to $54.60.

09:58 EDT Healthcare Trust provides update on investment activities - Healthcare Trust of America announced investment activities of over $617M, including approximately $257M of current investments and a development pipeline of approximately $360M. HTA also announced that it had closed on its previously announced disposition of assets in non-core markets at a gross sales price of over $67M. Through May 2021, HTA has closed or entered into exclusive negotiations on approximately $257M of investments. This includes closing on approximately $67M of investments totaling over 157,000 SF of GLA. In addition, HTA is under exclusive arrangements on approximately $190M of investments totaling approximately 469,000 SF of GLA, all located in HTA's key markets. The announced investments include HTA's $50M commitment to provide mezzanine debt in connection with the development of the Texas A&M Innovation Plaza, of which $15M has already been invested. These investments are expected to close by Q3 2021, subject to customary documentation and closing conditions. Additionally, HTA closed on the previously announced disposition of its 13 property portfolio located in Tennessee and Virginia at a gross sales price of $67.5M. HTA has negotiated a strategic partnership with Medistar Corporation to finance and co-develop the Texas A&M Innovation Plaza. The project includes a medical office and life sciences tower, a medical student housing structure and a parking garage. As part of this project, HTA will commit $50M of mezzanine debt to fund the construction of the 19-story, purpose-built student housing structure and parking garage. In addition, HTA has negotiated to be the exclusive equity partner and co-developer of the $215M Horizon Tower, a 485,000 square foot medical office and life sciences tower that is expected to commence construction in 2022.

09:54 EDT Perpetua Resources set to join Russell 2000 Index - Perpetua Resources announced that as part of the annual reconstitution of the Russell stock indexes, Perpetua Resources is expected to be included in the Russell 2000 Index and the broad-market Russell 3000 Index effective after the U.S. market opens on June 28, 2021.

09:50 EDT Forian set to join Russell 3000 Index - Forian is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

09:49 EDT Boeing, Navy use unmanned aircraft to refuel another aircraft - "For the first time in history, the U.S. Navy and Boeing have demonstrated air-to-air refueling using an unmanned aircraft - the Boeing-owned MQ-25 T1 test asset - to refuel another aircraft," the company said. During a test flight June 4, MQ-25 T1 successfully extended the hose and drogue from its U.S. Navy-issued aerial refueling store and safely transferred jet fuel to a U.S. Navy F/A-18 Super Hornet, demonstrating the MQ-25 Stingray's ability to carry out its primary aerial refueling mission. MQ-25 T1 will continue flight testing prior to being shipped to Norfolk, Virginia, for deck handling trials aboard a U.S. Navy carrier later this year. The Boeing-owned T1 test asset is a predecessor to the seven test aircraft Boeing is manufacturing under a 2018 contract award. The MQ-25 will assume the tanking role currently performed by F/A-18s, allowing for better use of the combat strike fighters and helping extend the range of the carrier air wing.

09:47 EDT Credicorp falls -6.3% - Credicorp is down -6.3%, or -$9.40 to $140.11.

09:47 EDT Ashford Hospitality rises 8.7% - Ashford Hospitality is up 8.7%, or 43c to $5.40.

09:47 EDT QTS Realty Trust rises 21.8% - QTS Realty Trust is up 21.8%, or $14.06 to $78.55.

09:42 EDT Carnival Cruise Line confirms plans for July restart - Carnival Cruise Line confirmed its plans to return to guest operations from Port of Galveston on July 3 with Carnival Vista, followed by the return of operations on Carnival Breeze on July 15. These cruises are available for guests who have received their final dose of a CDC-approved COVID-19 vaccine at least 14 days prior to the beginning of the cruise and have proof of vaccination, in accordance with current guidelines from the U.S. Centers for Disease Control and Prevention. "We appreciate the progress and support for our U.S. restart from the CDC and other key federal agencies; however, the current CDC requirements for cruising with a guest base that is unvaccinated will make it very difficult to deliver the experience our guests expect, especially given the large number of families with younger children who sail with us. As a result, our alternative is to operate our ships from the U.S. during the month of July with vaccinated guests," said Christine Duffy, president of Carnival Cruise Line. The other ship and port identified for a July restart is Carnival Horizon from PortMiami. Carnival continues to work with both the State of Florida and the CDC for Carnival Horizon sailings and plans to provide an update by Friday concerning protocols specific to these sailings to all booked guests. Carnival also said it will be advising guests and travel advisors about its plans for August sailings over the coming days.

09:38 EDT Surgalign announces collaboration with Inteneural Networks - Surgalign Holdings and Inteneural Networks announced that they have entered into a strategic collaboration agreement. Under the agreement, Surgalign will gain access to Inteneural's proprietary technology for evaluation of future integration within the Surgalign digital surgery portfolio. Inteneural is the developer and owner of proprietary intellectual property that allows computers to autonomously segment and identify neural structures in medical images and rapidly deliver reference information using machine learning alogrithims. These algorithms have potential for future applications in cranial and neurosurgery for referencing of tumor, aneurysm, stroke, and neurovascular structures using existing magnetic resonance imaging and computed tomography technology. The agreement provides for a period during which Surgalign will evaluate the Inteneural technology on an exclusive basis, and work with Inteneural to determine the feasibility of a more comprehensive collaboration.

09:36 EDT LTC Properties sells three assisted living communities in Wisconsin for $35M - LTC Properties announced the sale of three assisted living communities in Wisconsin that were part of LTC's Senior Lifestyle portfolio for $35M. The estimated gain from the sale of the properties, which include 263 assisted living units, is approximately $5.6M. These properties had a combined gross book value of $35.2M and a net book value of $28.3M. The net proceeds from the sale of approximately $34M were used to paydown LTC's unsecured revolving line of credit.

09:33 EDT NBC Olympics selects Sony broadcast, production equipment for Olympics - NBC Olympics, a division of the NBC Sports Group, has selected Sony Electronics to provide broadcast and production equipment for its production of the Games of the XXXII Olympiad, which take place in Tokyo, Japan, from July 23 - August 8. The announcement was made today by David Mazza, CTO & SVP, NBC Sports Group & Olympics, and John Studdert, Vice President, Media Solutions, Sony Electronics. NBC Olympics' crews will use nearly 100 Sony cameras to capture footage at event venues and record athlete interviews, press conferences, and other assignments that require studio and portable recording and capture. A selection of the Sony cameras, including the HDC-3500, will be used for IP-enabled transmission, while the rest will operate in SDI. The camera roster also features Sony's HDC-5500 and HDC-3500 4K/HDR, high-frame rate studio cameras for slow-motion replay footage, along with XDCAM camcorders including the PXW-Z750, PXW-Z450, PXW-X400 and PXW-Z280. NBC Olympics will use several of Sony's production switcher models - including the flagship XVS-9000 4K/3G/HD IP-ready switcher and the XVS-8000 and XVS-6000 4K/3G/HD video switchers designed for IP- and SDI-based production. Many of the switchers will be used in an IP-based environment and several will be designated for 1080P HDR production

09:33 EDT Q2 Holdings appoints Mike Volanoski as chief revenue officer - Q2 Holdings announced the appointment of Mike Volanoski as its chief revenue officer. As CRO, Volanoski is responsible for driving Q2's growth strategy in the North America region to meet increasing customer demand for Q2's proven solutions, the company said in a statement.

09:29 EDT Match Group name Jennifer Zephirin as first head of diversity, equity, inclusion - Match Group named Jennifer Zephirin as the company's first-ever head of diversity, equity, and inclusion, effective June 7. Zephirin will be based in New York and work closely with Match Group's executive leadership to build a team that will further develop and execute on the company's commitment to racial and social equity across its global portfolio. She will report to Shar Dubey, Chief Executive Officer of Match Group.

09:26 EDT Biogen rallies 3% ahead of FDA decision on Alzheimer's drug - Shares of Biogen are moving higher ahead of the FDA's decision on its experimental Alzheimer's medicine, aducanumab. The FDA action date for an approval decision is today. Citi analyst Mohit Bansal said last week that shares of Biogen could move to $150-$160 on rejection of aducanumab while approval could see the stock in the $400-$410 range. Biogen in premarket trading is up 3%, or $8.78, to $294.92.

09:23 EDT Bespoke Capital Acquisition, Vintage Wine Estates close business combination - Vintage Wine Estates announced that it has completed its previously announced business combination with Bespoke Capital Acquisition. The transaction, which was approved by BCAC shareholders at its meeting held on May 28, 2021, and also obtained approval from VWE shareholders, resulted in the combined company being renamed "Vintage Wine Estates, Inc." At the opening of trading on Tuesday, June 8, 2021, its common stock will commence trading on the Nasdaq Global Market under the new ticker symbol "VWE". The common stock and warrants are expected to be listed and posted for trading on the TSX under the new symbols "VWE.U" and "VWE.WT.U", respectively, on Wednesday, June 9, 2021 but will continue to be listed and posted for trading prior to that date under the current symbols "BC.U" and "BC.WT.U", respectively. In connection with the merger and related private placement, VWE and certain of its shareholders will receive approximately $306 million in cash proceeds. The funds received by the Company are expected to be used to expand and accelerate its proven growth strategy, driven by a combination of acquisition led and organic growth, across a well-balanced omni-channel model encompassing direct-to-consumer, wholesale and exclusive brand arrangements with national retailers. At closing, the Company will have 60,461,611 shares outstanding, representing a market capitalization of $617.9 million based on the June 4, 2021 closing share price of $10.22. The combined company will be led by Pat Roney, CEO and founder of VWE, and retain VWE's highly experienced management team, augmented by former Diageo CEO and Executive Chairman of BCAC, Paul Walsh, as non-executive Chairman. Key BCAC partners Rob Berner and Mark Harms have joined the Board of the combined company as non-executive directors alongside a strong group of independent directors including experienced wine industry executives and finance/legal executives with a focus on ESG and diversity.

09:22 EDT Installed Building Products buys General Ceiling & Part, no terms - Installed Building Products announced the acquisition of General Ceiling & Partitions. Founded in 1986, GCP is headquartered in Colorado Springs, Colorado and primarily installs drywall, framing, ceiling tiles, and firestopping/insulation for commercial customers. IBP also today announced the acquisition of Reliable Glass & Mirror, a Louisiana based provider of glass and mirror installation services to residential and commercial customers. "With approximately $11.5M of annual revenue, GCP further expands our commercial installation services to the compelling Colorado Springs market," stated Jeff Edwards, Chairman and Chief Executive Officer. "We also recently acquired Reliable Glass & Mirror increasing our presence within Louisiana. To date in 2021, we have acquired approximately $79M of annual revenues. Acquisitions remain a key component of our growth strategy and we continue to have a robust pipeline of acquisition opportunities across multiple geographies, products, and end markets. On behalf of everyone at Installed Building Products, I would like to welcome GCP and Reliable Glass & Mirror on to our team."

09:22 EDT Goodyear Tire completes acquisition of Cooper Tire & Rubber - The Goodyear Tire & Rubber (GT) announced that it has completed its acquisition of Cooper Tire & Rubber (CTB), finalizing the merger agreement made public on February 22. The combination unites two tire companies with complementary product portfolios, services and capabilities to create a stronger U.S.-based leader in the global tire industry. "The acquisition further strengthens Goodyear's leading position in the U.S., while significantly growing its position in other North American markets. The combined company will have the opportunity to leverage the strength of Goodyear original equipment and premium replacement tires, along with the mid-tier power of the Cooper brand, which has particular strength in the light truck and SUV segments. Goodyear expects to achieve approximately $165M in run-rate cost synergies within two years. The majority of the cost synergies will be related to overlapping corporate functions and realizing operating efficiencies. In addition, the combination is expected to generate net present value of $450M or more by utilizing Goodyear's available U.S. tax attributes. These tax attributes are expected to reduce the company's cash tax payments, positioning it to generate additional free cash flow. The expected cost synergies do not include manufacturing-related savings. Earnings and Balance Sheet. The acquisition is expected to be accretive to earnings per share within the first full year following closing, modestly improves Goodyear's balance sheet position and enhances the company's ability to de-lever," the company said.

09:20 EDT KBW appoints Matthew Kelley as director of research - Keefe, Bruyette & Woods named Matthew Kelley as Director of Research, based in New York. He succeeds Fred Cannon, who retired from the firm earlier this year. Prior to joining KBW, Mr. Kelley was a Principal and Director of Research at Sirios Capital Management, where he led many initiatives including strategic development and thought leadership, and also managed the firm's summer associate and associate analyst programs.

09:18 EDT MicroStrategy sees Q2 impairment of at least $284.5M on bitcoin - MicroStrategy said that based on the fluctuations in market price of bitcoin during Q2, it expects to incur an impairment loss of at least $284.5M related to its bitcoin for the three months ending June 30, 2021.

09:18 EDT LPL Financial appoints Shawn Mihal as EVP, Institution Services - LPL Financial announced that Shawn Mihal has joined the firm as executive vice president, Institution Services. Mihal will be responsible for further expanding the capabilities and services LPL offers to institutions and their clients, as well as supporting institutions' executive leadership and advisors in their long-term growth aspirations. He will report to LPL Chief Customer Care Officer and Managing Director Dayton Semerjian, working from the firm's Carolinas office. Mihal served as president of Waddell & Reed, Inc., the broker-dealer subsidiary of Waddell & Reed Financial, Inc. that LPL acquired April 30. Mihal succeeds Arthur Osman, who has had a 24-year career with LPL, joining the firm through the 2007 acquisition of UVEST Financial Services Group, Inc. Osman will work closely with Mihal to ensure a smooth transition and then take a step back to spend more time with his family beginning July 1.

09:15 EDT Neovasc Reducer System receives first national reimbursement in Europe - Neovasc announced that the Neovasc Reducer system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff Excluded Devices national catalogue. The National Health Service England has a nationwide purchase and supply system for specific categories of high-cost tariff-excluded medical devices used in specialized services designed to support the accelerated adoption of effective new technologies. These are devices NHS England has agreed should be paid for separately from the national tariff for a medical procedure. Hospital providers can now order the Reducer and bill the cost of the device directly to NHS England.

09:14 EDT Ambow Education announces strategic cooperation agreement with Kylinsoft - Ambow Education announced it has entered into a cooperation agreement with Kylinsoft, a Chinese software developer. "Pursuant to the Agreement, Ambow and Kylinsoft will join forces to enhance the cyberspace talents training system by designing training classes, offering career certification service, internship placement, employment service and co-founding industrial colleges, in a bid to foster an ecosystem of technologically advanced talent to meet the practical needs of national cyberspace development and ultimately boost the overall development of the Internet," the company said. Dr. Jin Huang, President and Chief Executive Officer of Ambow, commented, "This strategic cooperation marks an important step toward advancing our nation's homegrown cyberspace talent scheme. It is also an innovative, practical solution. As we move forward, we will combine our rich experience and advanced suite of solutions, products and services in career education and training space with Kylinsoft and its leading operating system technology capabilities to provide a comprehensive suite of talent training services across Kylinsoft series. We are committed to making a concerted effort to promote cyberspace talent growth initiatives and initiate a new chapter of talent cultivation in the sector."

09:12 EDT Zimmer Biomet announces new appointments to executive leadership team - Zimmer Biomet announced two new appointments to the Company's Executive Leadership Team. Wilfred van Zuilen has been appointed as President of Europe, Middle East and Africa. Additionally, Nitin Goyal, M.D. has been appointed to the newly created role of Chief Science, Technology and Innovation Officer. Both roles will report into Chief Operating Officer Ivan Tornos.

09:10 EDT CSX appoints Mark Wallace as EVP, Sean Pelkey as VP, acting CFO - CSX announced the appointments of Mark Wallace as executive vice president of CSX, Kevin Boone as executive vice president of sales and marketing, and Sean Pelkey as vice president and acting chief financial officer. In his new role, Mr. Wallace will focus on special projects and initiatives supporting the president and chief executive officer. Mr. Wallace continues to receive treatments for cancer but remains committed to helping deliver on the company's strategic growth initiatives. Boone, who most recently served as executive vice president and chief financial officer, joined the Company in September 2017 as a vice president responsible for investor relations. Pelkey joined CSX in 2005, and most recently served as vice president, finance and treasury.

09:09 EDT Advent signs contract with U.S. Department of Defense for wearable fuel cell - Advent Technologies announced that its subsidiary, UltraCell has received a contract from the U.S. Department of Defense to focus on completing the MIL-STD certification of UltraCell's 50 W Reformed Methanol Wearable Fuel Cell Power System The contract was signed with the U.S. Army DEVCOM Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance and Reconnaissance Center with funding through the Project Manager Integrated Visual Augmentation System , which works to enhance the situational awareness capabilities of Soldiers. This award is focused on advancing the Honey Badger for U.S. Army integration. The effort will drive efforts to complete the full MIL-STD and finalize integrated filtration for Cleaning Compound, Windshield NSN 9850-00-926-2275 to allow the use of logistically sound materials as the primary fuel source. The cutting-edge Honey Badger is optimized to operate on a Soldier-worn plate carrier or ruck carried for "on the move" battery charging and is designed to integrate with materials already in the U.S. Army supply chain. The versatile, lightweight fuel cell was recently selected by the DoD's National Defense Center for Energy and Environment to take part in its 2021 demonstration/validation program (see announcement here). The Honey Badger is the only fuel cell to take part in this program, which is led by the C5ISR Center to support the goal of having a technology-enabled force by 2028.

09:08 EDT Garrett Motion to expand production facility in Wuhan, China - Garrett Motion announced it plans to expand and modernize its existing production facility in Wuhan, China to meet increasing customer demand. Garrett's Wuhan plant opened in 2013 and currently serves major local and global automakers. The expansion is expected to increase the size of the state-of-the-art facility by approximately 50% and is scheduled for completion in the first quarter of 2022. China net sales in 2020 increased over 32% for the year led by a record performance in the fourth quarter following extended plant closures in Wuhan and Shanghai during the first quarter due to the COVID-19 pandemic. Demand for Garrett's differentiated technologies has been driven by modern engine architectures with downsized engines, the growth in electrified powertrains, and more stringent fuel efficiency and emissions regulations, such as China VI. Currently, Garrett estimates turbo penetration in China for passenger vehicles is approximately 60%, and growing.

09:07 EDT GrowGeneration's Power Si signs distribution agreement with GreenPlanet - GrowGeneration announced that Power Si, a proprietary brand operated and owned by GrowGen, has signed an exclusive distribution agreement with GreenPlanet Wholesale, one of Canada's hydroponic distributors. "We are thrilled that, at long last, Canadians will have the opportunity to experience firsthand what Power Si brings into their gardens. This is a groundbreaking product with proven success in the garden and a huge following in countries around the world. At GreenPlanet Wholesale, we are committed to bringing our customers the best products the industry has to offer, and Power Si is another example of this. This product has been long-awaited in the Canadian Marketplace and we could not be prouder to partner with the great team at Power Si. I can't wait to hear from our growing community as they begin to use this exciting new product." stated Mark Walman, Chief Operating Officer for GreenPlanet Wholesale.

09:06 EDT EnWave appoints Brad Lahrman as CEO of NutraDried - EnWave Corporation has appointed Brad Lahrman as the new CEO of NutraDried Food Company, EnWave's wholly-owned operating subsidiary. Lahrman brings fifteen years of leadership experience in mid-market consumer products companies, including most recently with Schouten USA, a major plant-based protein company, Lightlife Foods, a leading plant-based protein company that was acquired by Maple Leaf Foods in 2017, and earlier with Campbell Soup Company. The Company and its Board of Directors is pleased to welcome Lahrman into the executive management team to lead the next phase of commercial growth at NutraDried. Working closely with EnWave's management team, Lahrman will drive the development of a refined multi-channel sales strategy at NutraDried, including the development of new products for in-house brands, private-label and co-manufacturing, with products that leverage the use of EnWave's Radiant Energy Vacuum dehydration technology. Mr. Lahrman will report directly to EnWave's CEO, Mr. Brent Charleton. Additionally, EnWave's Chief Financial Officer, Mr. Dan Henriques, will continue to serve in a dual-capacity as Chief Operating Officer at NutraDried. Upon his appointment as CEO of NutraDried, the Company has granted Mr. Lahrman an aggregate of 800,000 incentive stock options, subject to the terms of the Company's Stock Option Plan, that are exercisable at the last closing price of the Company's common shares on the TSX Venture Exchange on June 7, 2021. The incentive stock options are exercisable for a term of five years expiring on June 7, 2026 and will vest in one-third increments over three years in accordance to the provisions set out in the Plan, or as otherwise required by the TSXV. The grant of the equity incentive stock options is subject to approval by the TSXV.

09:05 EDT HyreCar Set to join the Russell 3000 Index - HyreCaris set to join the broad-market Russell 3000? Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4. "We have worked hard to get to this point, taking the company from concept to now joining the Russell 3000, something that we believe will attract broader interest in Hyrecar from institutional investors and investment funds," said Joe Furnari, CEO. "I'm proud of the tremendous progress we have made this year, both operationally and driving top line growth that should continue as we execute on our strategic plans in 2021." Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. Membership in the US all-cap Russell 3000(R) Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000? Index or small-cap Russell 2000? Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

09:02 EDT Nucor to acquire insulated metal panels business from Cornerstone Building - Nucor (NUE) announced that it has signed a definitive purchase agreement to acquire Cornerstone Building Brands' (CNR) insulated metal panels business for a cash purchase price of $1B, or approximately 10x pre-pandemic EBITDA inclusive of expected synergies. Adjusting for the net present value of associated tax benefits, the realized effective purchase price for Nucor is approximately $900M. The transaction is expected to close later this year, pending regulatory approvals. IMP products are wall and roof panel solutions comprised of an energy efficient foam core sandwiched between two layers of steel or aluminum and are available in a variety of widths, thicknesses and exterior finishes. The IMP business Nucor is acquiring from Cornerstone Building Brands has seven manufacturing facilities located throughout North America. These locations complement the footprint of Nucor Buildings Group, as well as the company's existing IMP business, TrueCore. With this acquisition, Nucor will be purchasing two valued legacy brands, CENTRIA and Metl-Span, which provide a full range of products to service high-end architectural applications to more functional and quickly expanding cold storage and warehousing applications.

09:00 EDT Orbital Energy appoints Paul Addison to board of directors - Orbital Energy Group (OEG) announced the appointment of veteran financial executive Paul Addison, to its board of directors, effective immediately. Addison joins the board as an independent director, expanding the Board to 8 directors, 5 of whom are independent. Addison has also served as an independent director of FirstEnergy (FE); where he was Chairman of the Finance Committee and a member of the Audit Committee as a designated financial expert.

08:56 EDT PriceSmart announces May net merchandise sales - PriceSmart announced that net merchandise sales in May increased 16.3% to $286.4M from $246.3M in May a year earlier. Foreign currency exchange rate fluctuations impacted net merchandise sales negatively by 1.6%, or $3.8M, versus the same one-month period in the prior year. There were 47 warehouse clubs in operation at the end of May 2021 and 45 warehouse clubs in operation at the end of May 2020. For the five weeks ended May 30, 2021, comparable net merchandise sales for the 45 warehouse clubs open at least 13 1/2 full months increased 12.0% when compared to the same period last year. Foreign currency exchange rate fluctuations impacted comparable net merchandise sales negatively by 1.6%, or $4.4M, versus the same period in the prior year. The 12-month membership renewal rate was 87.6% for the period ended May 31, 2021, an increase from the 81.5% and 80.5% 12-month renewal rate for the periods ended February 28, 2021 and August 31, 2020, respectively. Fiscal year to date, which includes the nine months ended May 31, 2021, net merchandise sales increased 7.3% to $2,594.3M from $2,418.8M for the nine months ended May 31, 2020. Foreign currency exchange rate fluctuations impacted net merchandise sales negatively by 2.7% or $66.3M versus the same nine-month period in the prior year.

08:55 EDT EXFO Inc. trading halted, news pending

08:51 EDT ViaSat's first ViaSat-3 completes payload integration, performance testing - Viasat (VSAT) announced the first satellite in its ViaSat-3 global constellation, which will serve the Americas and the surrounding oceans regions, has reached a major milestone with completion of payload integration and performance testing, and shipment to the Boeing (BA) Satellite Systems facility in El Segundo, California. The payload will be integrated with the bus module and the satellite will then undergo a complete series of environmental testing to simulate the rigors of launch and operation in the harsh environment of space. Launch is targeted for early calendar year 2022. Each ViaSat-3 satellite is expected to generate over 20kW of payload power, making it among the highest-power commercial satellites ever built. The ViaSat-3 constellation is anticipated to have roughly eight times more capacity than Viasat's current fleet combined. Concurrently, the ViaSat-3 ground segment has made significant progress over the past year in preparation to support the upcoming launches. Viasat is also working on the construction of the payloads for the second and third ViaSat-3-class satellites, ViaSat-3 and ViaSat-3. The ViaSat-3 payload is expected to be delivered to Boeing in the latter part of FY2022.

08:48 EDT entrinsic bioscience receives $49M from Jefferies Funding - entrinsic bioscience announced that it has secured $49M in non-dilutive growth capital from Jefferies Group's subsidiary, Jefferies Funding. Jefferies acted as sole lender to EBS. CFO Mario Wanderley summarized the transaction: "We are very proud to have a firm of Jefferies' caliber backing us. Our insurance policy-backed deal was made possible by the significant value and broad applications of our intellectual property portfolio, which was subject to great scrutiny and due diligence by our financing partners who concluded that the facility amount represents a fraction of the value of our IP."

08:46 EDT Digital Ally announces formation of Digital Ally Healthcare - Digital Ally announced the formation of Digital Ally Healthcare to pursue opportunities in the healthcare industry. This business initiative is part of the Company's strategic plan to diversify its product and service offerings to address larger target markets that have significant growth prospects. Digital Healthcare's goal is to create recurring sources of revenue, expand its profit margins, achieve sustainable positive cash flow and fuel future growth. On June 4, 2021 Digital Healthcare, a wholly-owned subsidiary of the Company, entered into a venture with Nobility LLC, an eight-year old revenue cycle management company servicing the medical industry. Digital Healthcare is capitalizing the venture with $13.5 million to support the venture's business strategy to make acquisitions of RCM companies. Digital Healthcare owns 51% of the venture that entitles it to 51% of the distributable cash as defined in the venture's operating agreement plus a cumulative preferred return of 10% per annum on its invested capital. Nobility will receive a management fee and 49% of the distributable cash, subordinated to Digital Healthcare's preferred return. The venture currently has two target acquisitions under letters of intent and is negotiating for the purchase of another RCM portfolio. The total revenue run rate of these acquisitions is approximately $5.0 million annually with significant profit margins expected after the venture implements cost reductions and economies of scale. The total purchase price of the Targets are approximately $5.0 million with cash at closing expected to average 75% of the purchase prices and the balances generally paid over several years subject to achievement of certain milestones. The closings are expected to occur over the next several months and are subject to final due diligence and negotiation of definitive agreements. Upon completion of the acquisitions the venture will process and submit the medical reimbursement claims of its physician clients to commercial health insurance companies and Medicare/Medicaid for the services the physicians have rendered to their patients so they can receive payments. The venture will receive a percentage of the cash collected for its fees. The RCM agreements with physician clients generally renew automatically on an annual basis. Nobility will manage the venture with certain administrative assistance from Digital Healthcare. Nobility has a deep and experienced management team with many years of combined medical billing experience. It is based in Scottsdale Arizona with an overseas office and staff. Nobility has a proven track record of being able to purchase RCM companies at favorable prices and terms, cut costs and improve client performance levels and profit margins while retaining the client portfolios acquired. Because these are service-based businesses, the largest cost is labor. Nobility has developed the infrastructure and management expertise to cut these costs while providing superior service levels through its management team and staff. Nobility operates an overseas office and staff that provides back-office claims processing, submission and follow-up services which will support the venture's operations. Its overseas labor and office costs are generally much lower when compared to higher cost United States-based staffing and facility costs. We intend to retain United States-based staff members of the acquired RCM companies who have key client facing relationships to provide seamless services and improve client retention levels.

08:43 EDT Cullinan receives IND clearance for CLN-049 - Cullinan Oncology announced that the U.S. Food and Drug Administration has cleared Cullinan Florentine's IND application for CLN-049, a FLT3 x CD3 bispecific antibody for the treatment of relapsed/refractory acute myeloid leukemia.

08:42 EDT Thermo Fisher announces collaboration with University of Sheffield - Thermo Fisher Scientific and the University of Sheffield have joined forces to develop advanced end-to-end workflows for the characterization and monitoring of complex oligonucleotide and mRNA products. "This collaboration brings together the University of Sheffield's extensive research expertise and Thermo Fisher's cutting-edge sample preparation, liquid chromatography, high resolution accurate mass mass spectrometry and data interpretation software technologies to enable the development of streamlined analytical workflows and robust fit-for-purpose processes," the company said.

08:41 EDT GoDaddy announces new integrations with Amazon, eBay, Instagram in Canada - GoDaddy (GDDY) announced that Canadian customers can now sell their products on Amazon (AMZN) and eBay (EBAY) through GoDaddy Websites + Marketing. "The new Marketplaces feature is especially timely as more Canadian small businesses sell online. For example, 68% more GoDaddy Canada customers with an online store were actively selling products during the first three months of 2021, versus the same period last year. Canadian entrepreneurs and small business owners can now sell their products on two of the world's largest online marketplaces, Amazon and eBay, through a single dashboard view. They can also now use Websites + Marketing to publish posts directly to Instagram, enabling them to easily promote their products and brand online," GoDaddy stated. "While selling online has been a key driver of sales, especially amid the COVID-19 pandemic, it's never been more important to ensure businesses are set up for digital success. With the integrations with Amazon, eBay and Instagram, we're excited to offer these powerful new features as part of our growing suite of ecommerce and digital marketing tools to ensure Canadian businesses can create a professional and unique online shopping experience to thrive in the digital economy," said Anne De Aragon, VP and Country Manager, GoDaddy Canada.

08:40 EDT Novan announces in vitro, in vivo results for NVN4100 - Novan announced positive proof-of-concept in vitro results and informative in vivo results with its new chemical entity, NVN4100, explored as a potential product candidate for topical antimicrobial indications in companion animal health. Novan initiated exploratory work to evaluate NVN4100 and engaged with animal health experts at Scullion Strategy Group, LLC to oversee the Company's initial animal health studies and to assess technical feasibility and market potential. The in vivo and in vitro studies were conducted by independent third party animal health research organizations. The exploratory studies were conducted to determine the minimum inhibitory concentration and minimum bactericidal concentration of NVN4100 using broth dilution antimicrobial susceptibility testing against a set of clinically relevant microorganisms. Results from the in vitro assay demonstrated that NVN4100 had both inhibitory and bactericidal effects for a variety of pathogens. The tested pathogens include both antimicrobial resistant and antimicrobial susceptible strains of the most prevalent species associated with skin and ear conditions in animal health, including Escherichia coli, Pseudomonas aeruginosa, Staphylococcus pseudintermedius, and Staphylococcus schleiferi. Additionally, in collaboration with an independent third party animal health research organization, Novan established a model of canine pyoderma, one of the most common skin conditions of dogs that is often resistant to first-line antimicrobials, to evaluate topically applied NVN4100 in an in vivo setting. The in vivo results suggest that the canine pyoderma model may serve as an appropriate tool to facilitate further development of NVN4100 as an alternative therapy to systemic and topical antimicrobials for treatment of canine superficial pyoderma or other dermatology indications. Based on the results to date and the availability of funding, Novan intends to conduct additional studies and formulation work with NVN4100 to build a robust data set and engage with potential collaborators and strategic partners moving forward. The Company seeks to publish the full data set from the companion animal health exploratory studies at an upcoming scientific congress and/or in a peer-reviewed publication.

08:37 EDT MICT, Inc. approves $60M capitalization for Magpie Securities - MICT announces its Board of Directors has approved a $60M capital injection from MICT to its wholly owned subsidiary, Magpie Securities, which developed and will operate the Company's online stock trading platform from Hong Kong. The transfer to Magpie will be in two tranches. The first $30M will be in the form of equity capital. Then, upon Hong Kong Securities and Futures Commission approval, the second $30M will be by way of intercompany subordinated loan.

08:36 EDT Colony Capital announces sale of other equity & debt portfolio - Colony Capital (CLNY) announced it has reached an agreement to sell the bulk of its OED portfolio of real estate assets to Fortress Investment Group a leading, diversified global investment manager, for gross proceeds of $535M. The OED Portfolio Sale proceeds are in line with the net equity carrying value of the underlying assets as of March 31. The OED Portfolio Sale advances several of the Company's stated strategic goals Boost Digital Firepower - Over half-billion dollars of capital available to fuel high-quality digital investments, harvested at levels in line with net carrying values Simplification - Substantial reduction in organizational complexity generates estimated overhead cost savings of over $18M allows enhanced focus on digital, and simplifies investor analysis Enhance Liquidity, Reduce Leverage - The OED Portfolio Sale increases corporate liquidity to over $1.2 billion on a pro forma basis, while at the same time reducing consolidated investment-level debt by $945 million "This transaction is a watershed moment for us, a big step towards our Finish-The-Mission goal as we rotate to a fully-digital business. Not only are we freeing up over a half-billion dollars to redeploy into digital, we're simplifying our business, making it easier to manage and to understand," said Marc Ganzi, President and CEO of Colony Capital. "Fortress is a world-class organization, so I know these assets will be stewarded in the most responsible way going forward, allowing us to maintain our singular focus on building the most compelling digital infrastructure REIT in the world." "We are thrilled to announce this win-win transaction with Colony," said Fortress Managing Director Noah Shore. "It's a perfect fit with our existing business and our deep wells of experience and expertise in managing highly complex investments across a full range of asset types, structures, industries and geographies." The transaction will result in digital assets under management accounting for 80% of the Company's pro forma AUM, with its Wellness Infrastructure segment and ownership stake in the publicly-listed shares of Colony Credit Real Estate, (CLNC), which are not included in the sale along with a small number of OED assets, constituting its remaining material legacy assets.

08:35 EDT IRIS.TV, SpotX partner for video-level contextual targeting in CTV - IRIS.TV has tapped SpotX to bring industry-standard contextual segments to SpotX's supply, to enable marketers to target and verify the category of video on all screens.

08:33 EDT Hill International to manage on-call professional service program for LAWA - Hill International announced it was selected by Los Angeles World Airports, a Department of the City of Los Angeles, to manage airport concessions development, tenant projects, and airport commercial analysis and development at LAWA properties including Los Angeles International Airport, Van Nuys Airport, and Palmdale Landholdings. Work will be carried out through task-order contracts under a three-year indefinite delivery/indefinite quantity contract with two potential one-year extensions. Task orders will encompass a range of projects to improve the use and efficiency of airport properties.

08:30 EDT Aeterna Zentaris engages Michael Levy as scientific consultant - Aeterna Zentaris announced it has engaged neuroimmunologist, Michael Levy, MD, PhD, Research Director of the Division of Neuroimmunology & Neuroinfectious Disease at Massachusetts General Hospital as a scientific consultant to support the development of the Company's targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis optica spectrum disorder. Dr. Levy will provide scientific support and advice to Aeterna Zentaris in the field of inflammatory CNS disorders, autoimmune diseases of the nervous system, and NMOSD. In January 2021, Aeterna Zentaris entered into an exclusive patent license agreement and research agreement with Julius-Maximilians-University of Wuerzburg, Germany for worldwide rights to develop, manufacture and commercialize AIM Biologicals for the potential treatment of NMOSD. The Company is currently conducting in-vitro and in-vivo assessments to identify and characterize an AIM Biologicals-based development candidate for the treatment of NMOSD and develop manufacturing process for the selected candidate.

08:26 EDT Kaiser Aluminum receives ASI Performance Standard Provisional Certification - Kaiser Aluminum Corporation announced that its rolling mill near Evansville, Indiana has received the Performance Standard Certification with Provisional status from Aluminum Stewardship Initiative for its ingot casting centers, rolling mills and finishing production centers. The Warrick facility is one of only four dedicated rolling mills in North America for the packaging industry and is the first facility of its type in this market to achieve ASI Performance Standard certification for responsible sourcing and stewardship of aluminium.

08:25 EDT Faro Technologies acquires HoloBuilder for $34M - FARO Technologies announced the acquisition of HoloBuilder. "HoloBuilder brings to FARO its leading photogrammetry-based 3D platform, which delivers hardware agnostic image capture, registration and viewing to the fast-growing Digital Twin market. With an initial focus on Construction Management, HoloBuilder's technology platform provides general contractors a solution to efficiently capture and virtually manage construction progress using off-the-shelf 360 degrees cameras," the company said. "The high-value that digitalization brings to the AEC and Operations & Maintenance industries creates significant market opportunity for FARO," stated Michael Burger, FARO President and CEO. "The addition of HoloBuilder to our offering accelerates the reality of a true end-to-end Digital Twin solution and advances our strategic objective of increased recurring revenue through market share gains in this large and growing segment." Under terms of the agreement, HoloBuilder shareholders received a cash payment of $34M. As of April 30, 2021, HoloBuilder had $4.0M in annual recurring revenue with a compounded annual growth rate of nearly 75% since 2019. The transaction closed on June 4 and was funded with available cash reserves. Alantra acted as exclusive financial adviser to HoloBuilder.

08:24 EDT Veru: Sabizabulin showed evidence of antitumor efficacy in Phase 1b/2 study - Veru announced the presentation of the Phase 1b/2 clinical trial update of sabizabulin, an oral cytoskeleton disruptor which in prostate cancer also disrupts androgen receptor transport, to treat men with metastatic castration resistant prostate cancer who failed at least one androgen receptor targeting agent, at the American Society of Clinical Oncology 2021 Annual Meeting being held June 4-8, 2021. The Phase 1b/2 clinical study was designed as a dynamic study with an initial 3+3 standard safety study component followed by an expanded study with increases in dose and schedule. The Phase 1b/2 clinical trial enrolled 80 men and is ongoing with patients in both the Phase 1b and 2 components still on study. Highlights of the study presentation are as follows: Sabizabulin oral daily dosing was well tolerated, and the most common adverse events, being mostly Grade 1 and 2, were diarrhea, fatigue, nausea, and decrease in appetite. There was no evidence of clinically relevant neutropenia or neurotoxicity. Safety profile was similar to that reported in package inserts for androgen receptor targeting agents, abiraterone and enzalutamide. Clinically meaningful and durable evidence of objective tumor responses were observed in patients on 63mg oral daily dosing schedule: In the ITT population with measurable disease, the ORR was 20.7%.

08:23 EDT Macquarie Infrastructure to sell Atlantic Aviation business to KKR for $4.48B - Macquarie Infrastructure (MIC) and KKR (KKR) announced the signing of a definitive agreement for MIC to sell its Atlantic Aviation business to KKR for $4.48B in cash and assumed debt and reorganization obligations. The purchase price implies a multiple of Atlantic Aviation's 2019 EBITDA of 16.2 times. MIC expects to receive $3.53B at closing following the reorganization of MIC into a limited liability company, Macquarie Infrastructure Holdings LLC. The reorganization was approved by MIC shareholders on May 6 and is expected be completed shortly before the closing of the Atlantic Aviation sale. The Atlantic Aviation sale is expected to result in cash proceeds of approximately $3.3B being available for distribution to unitholders after a disposition payment by MIH to MIC's external manager of approximately $227M. The disposition payment was calculated in accordance with the disposition agreement entered into by and between MIC and the company's external manager on October 30, 2019. The MIH board of directors is expected to authorize a cash distribution of approximately $37.35 per unit following closing of the transaction. The sale of Atlantic Aviation is expected to close in Q4, subject to customary regulatory approvals and approval from MIC shareholders. MIC expects to seek approval of the Atlantic Aviation sale at a special meeting of shareholders to be conducted as soon as practical following clearance of the related proxy statement by the Securities and Exchange Commission. KKR is making its investment in Atlantic Aviation primarily through its Global Infrastructure Investors and Core Investments strategies.

08:23 EDT TFF Pharmaceuticals to host KOL perspectives on thin film freezing applications - TFF Pharmaceuticals announced that it will host a key opinion leader perspectives webinar on thin film freezing applications, with a focus on TFF Tacrolimus for lung transplant and TFF approaches to improving vaccines. The webinar will be held on Tuesday, June 15, 2021 at 4:00pm Eastern Time. The webinar will feature presentations by KOLs Deborah Jo Levine, MD, UT Health San Antonio, Ted Ross, Ph.D., University of Georgia, and Kartik Chandran, Ph.D., Albert Einstein College of Medicine. Dr. Levine will provide background on lung transplantation, the current toxicity limitation of oral tacrolimus for immunosuppression, and the potential improvements with an inhaled formulation of tacrolimus. Dr. Chandran will discuss the benefits of using the TFF technology to create a dry powder pulmonary formulation for the rVSV vaccine against COVID-19. Dr. Ross will discuss his experience utilizing the TFF process for creating a universal influenza vaccine for pulmonary delivery and its potential benefit over the existing annual vaccination. TFF Pharma's management team will also provide an update on its internal pipeline and several upcoming planned clinical data releases for TFF TAC and TFF voriconazole.

08:22 EDT Terra Tech Corp to sele non-operating propery for $2.6M - Terra Tech Corp. announced that the Company entered into an agreement for the sale of its non-operating N. 4th Street property in Las Vegas, NV. Based on local zoning changes, the property cannot be used for any cannabis related activities. The sale price of $2.6M results in an approximate $900K balance sheet improvement, after paying off the existing $1.6M mortgage on the property and related sales fees. The sale also eliminates the current monthly burn of carrying the property, including mortgage, taxes, and other associated costs. The closing of the sale is subject to customary conditions and is expected to occur by early August 2021.

08:20 EDT Bionano Genomics appoints Jason Priar as CCO - Bionano Genomics announced that Jason Priar has joined the company as its Chief Commercial Officer. For Bionano, he will lead the commercial teams across the platform and services businesses to drive sales and market access with third party payors. After time with Forest Laboratories as a pharmaceutical detailer, he was selected for sales leadership positions at GeneDx, Sema4 and PerkinElmer Genomics with responsibilities covering sales, marketing, customer support and managed care across North America, Europe, China and India.

08:19 EDT Service Properties amends management agreement with Hyatt - Service Properties Trust (SVC), or SVC,announced that it reached an agreement with a subsidiary of Hyatt Hotels( H) Corporation, or Hyatt, to amend their previous management agreement for 22 Hyatt Place hotels owned by subsidiaries of SVC. Under the amended agreement, Hyatt will continue to manage 17 of the hotels for a 10-year term effective as of April 1. Among other terms, the new agreement with Hyatt provides as follows: SVC's owner's priority return is set at $12M annually, supported by a $30M guaranty for 75% of the aggregate annual owner's priority return beginning in 2023. A management fee equal to 5% of gross room revenues payable to Hyatt will be an operating cost paid senior to SVC's owner's priority return. Following payment of SVC's owner's priority return and reimbursement of certain advances, if any, Hyatt may earn a 20% incentive management fee and SVC will receive the remaining cash flow. SVC will fund approximately $50M for renovations expected to be completed by the end of 2022. As such funding is advanced by SVC, the aggregate annual owner's priority return due to SVC under the amended agreement will increase by 6% of the amounts funded.

08:18 EDT Aziyo comments on voluntary recall of FiberCel fiber viable bone matrix - Aziyo Biologics on June 2, 2021 issued a voluntary recall pertaining to a single donor lot of its FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and spinal procedures. Notice of the voluntary recall was issued to hospitals that received product from this specific lot following the Company's learning of post-surgical infections in patients treated with FiberCel, including some patients that tested positive for tuberculosis. The lot consists of 154 units of FiberCel, all derived from a single donor, that were shipped to facilities in 20 states. Aziyo is investigating the source of the infections in coordination with its distributor, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention. The Company is in the process of recovering the unused units from this lot. At present, the Company has no reason to believe any other units of FiberCel are affected by this situation. "Patient health and safety are our highest priority. Accordingly, we have implemented this voluntary recall and instructed hospitals that received FiberCel product from this specific donor lot to immediately quarantine and return any remaining product to us," said Ron Lloyd, Aziyo's president and chief executive officer. "We are committed to a thorough, timely and transparent investigation into the root cause of these infections." Out of an abundance of caution, sales of FiberCel will be suspended by its distributor until further notice. Given the uncertainty regarding any potential impact to Aziyo's business resulting from the recall and the pause in FiberCel sales, Aziyo is suspending its revenue guidance for full year 2021, previously announced on May 4, 2021.

08:16 EDT TS Innovation Acquisition, Latch complete business combination - Latch and TS Innovation Acquisitions Corp., a publicly traded special purpose acquisition company launched by leading real estate owner, developer, operator, and investment manager Tishman Speyer Properties, announced that on June 4, 2021, the parties officially completed their previously announced transaction that resulted in Latch becoming a public company. The transaction was approved at a special meeting of the TSIA stockholders on June 3, 2021. Latch's common stock and warrants will begin trading on the Nasdaq Global Select Market today under the ticker symbols "LTCH" and "LTCHW," respectively. In connection with the transaction, Latch has received approximately $453 million in cash proceeds, net of fees and expenses funded in conjunction with the closing of the business combination, which includes $190 million from a previously announced private placement of common stock. The proceeds will be used to fund initiatives to drive growth, such as growing the number of units on its platform, expanding offerings to additional asset classes, and spreading to new geographies. As announced on March 31, 2021, Latch's Board of Directors is comprised of seven directors, including: Peter Campbell, Tricia Han, Raju Rishi, J. Allen Smith, Rob Speyer, Luke Schoenfelder, and Andrew Sugrue. Latch's management team will continue to be led by Schoenfelder, Brian Jones, Chief Technology Officer and Co-Founder, Ali Hussain, Chief Operating Officer, and Garth Mitchell, Chief Financial Officer.

08:15 EDT Poshmark initiating comprehensive internal and external search for CFO

08:14 EDT Vera Bradley, Classic Accessories announce outdoor living collection - Vera Bradley and Classic Accessories announced their limited-edition, co-branded outdoor living collection will debut today. The two brands collaborated to create the Vera Bradley + Classic Accessories exclusive outdoor living collection that combines the myriad of colorful and bright floral, paisley, ikat, toile and ditsy pattern designs customers know and love from Vera Bradley with the trusted quality and functionality they expect from Classic Accessories. The Vera Bradley + Classic Accessories collection includes furniture covers, seat and lounge cushions, accent pillows, umbrellas, outdoor rugs and more. Each style is available to mix and match in a selection of Vera Bradley's best seasonal prints, along with patterns created exclusively for the collection.

08:13 EDT Borqs Technologies receives 1.7M sq. ft. land use rights in China - Borqs Technologies announced that it has signed a supplementary agreement with the Huzhou South Taihu New Development Commission in which Borqs is granted land use rights to 240 Chinese acres to build up a 5G Industrial Park particularly for 5G mobile technologies R&D and incubation activities, IoT products manufacturing and showcases, as well as hosting facilities for visitors. The first phase of product assembly facilities has already begun and is anticipated to be operational by the end of June 2021.

08:13 EDT Onex Partners V to acquire Newport Healthcare, terms not disclosed - Onex Corporation announced that Onex Partners V has agreed to acquire Newport Healthcare, in partnership with the company's management team. Newport is a leading provider in the United States of evidence-based healing centers for teens and young adults struggling with primary mental health issues. Newport offers a family-systems approach, providing gender-specific, individualized, integrated programs that encompass clinical therapy, academic support, and experiential practices. Offerings include residential treatment centers, Partial Hospitalization Programs, and Intensive Outpatient Programs. Newport nurtures the physical, psychological, social, educational, and spiritual needs of individuals, from a foundation of compassionate care, clinical expertise, and unconditional love. Newport's primary mission is to empower lives and restore families. Healthcare is one of Onex Partners' core investment verticals and the firm has a long and successful track record investing in the sector, including in behavioural health. The transaction is anticipated to close in the third quarter of 2021 subject to customary closing conditions and regulatory approvals. The terms of the transaction are not being disclosed at this time.

08:12 EDT Duke Energy to build 250-MW Pisgah Ridge Solar project in Texas - Duke Energy Sustainable Solutions (DUK) announced the start of construction of the 250-megawatt Pisgah Ridge Solar project in Navarro County, Texas. Once in operation, it will be the largest utility-scale solar facility in Duke Energy Sustainable Solutions' fleet. Charles River Laboratories International (CRL) has signed a virtual power purchase agreement for 102 MW of the project over 15 years. This commitment will address the entirety of the company's North American electric power load with clean, renewable energy by 2023. Two other corporations have signed separate 15-year VPPA agreements for the remaining 148 MW of solar energy generated by the Pisgah Ridge Solar project. All three VPPAs associated with the site will settle on an as-generated basis tied to the project's real-time energy output. The engineering and construction for the project are being performed by Moss, while Duke Energy Sustainable Solutions will own and operate the project. The team expects to achieve commercial operation of Pisgah Ridge Solar by the end of 2022. The project is expected to employ 200 to 300 workers at peak construction. Along with indirect economic benefits that accompany solar project development, such as increased local spending in the service and construction industries, the Pisgah Ridge Solar facility will also have a positive economic impact on the local community by providing significant tax revenues for the Corsicana Independent School District. Duke Energy Sustainable Solutions currently operates nearly 1,500 MW of wind, 500 MW of solar and a 36 MW battery storage facility in Texas. The addition of the 250 MW Pisgah Ridge Solar facility, which will be located outside of Dallas, will generate enough energy to power approximately 63,000 additional residences in the state.

08:11 EDT Magna announces Surface Element Lighting technology - Magna is pushing vehicle design possibilities with its new innovative Surface Element Lighting technology which offers a new palette of options for automotive designers. First-to-market on the all-electric 2021 Volkswagen ID.4, Surface Element Lighting is contained within a compact package, providing a homogeneous appearance and customizable, affordable LED lighting options for exterior vehicle applications.

08:10 EDT Kratos reports sales of virtual ground system products to over 20 customers - Kratos Defense & Security Solutions announced that in the first quarter of 2021 it delivered products supporting the satellite industry's movement toward virtualized ground systems to 24 customers around the globe. These included products in Kratos' quantum and SpectralNet lines, both of which are part of its OpenSpace family of dynamic, virtual ground solutions. Kratos' OpenSpace quantum products offer software versions of satellite ground system components which traditionally have been implemented as hardware, such as modems and front-end processors, needed to communicate with the satellite or its payload. Kratos' quantum products have been in use by hundreds of satellite operators around the globe supporting tens of thousands of satellite passes per month.

08:09 EDT CPI Aerostructures to restate FY20 financial statements - CPI Aerostructures announced that the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30, 2020 as filed with the SEC will be amended and that the financial statements which were included therein should no longer be relied upon due to errors in such financial statements. Similarly, management's reports on the effectiveness of internal control over financial reporting, press releases, and investor communications describing the Company's financial statements for such periods should no longer be relied upon. On May 17, 2021, the Company filed a Notification of Late Filing on Form 12b-25 with the SEC which stated that it was unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 by the prescribed due date without unreasonable effort or expense due to, among other things, long-term COVID-19 related absences of personnel whose functions are essential to the financial closing process. After the filing of the Form 12b-25, as part of the delayed financial closing process, management identified errors relating to the recording and reporting of inventory costing and related internal controls during its inventory testing procedures for the preparation of the Company's financial statements for the quarterly period ended March 31, 2021. The Company announced in a press release on June 1, 2021 that it had not timely filed the Delayed Form 10-Q because additional time was needed to complete the Company's delayed financial closing process and to evaluate the scope and impact of the Inventory Costing Errors. Currently, the Company's internal review indicates that the Inventory Costing Errors resulted from the sequence in which Company personnel used the Company's manufacturing software to receive manufactured goods into stock and code errors in a customization of the Company's core manufacturing software that miscalculated average costs of certain manufactured items. The Company believes that the Inventory Costing Errors resulted in incorrectly reported inventory values and reported income for the quarterly periods ended March 31, 2020, June 30, 2020, September 30, 2020 and for the year ended December 31, 2020. The errors affect the income reported with respect to the Company's product lines for which revenue is recognized when a product ships to customers, which accounted for approximately 15% of total 2020 revenue. The Company believes that the errors did not affect income reported with respect to the Company's products for which revenue is recognized over time using percentage of completion accounting. The Company is conducting an analysis of the impact of the Inventory Costing Errors on previously reported financial results. The Company currently estimates fiscal year 2020 net income will be reduced by between $1.9 million and $2.3 million, spread over the four fiscal quarters. The Company believes that the Inventory Costing Errors affect neither the reported revenue nor the Company's reported cash flows for the affected periods. The Company expects to amend its Annual Report on Form 10-K for the year ended December 31, 2020 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020, and to restate the financial statements and other disclosures contained therein as soon as reasonably practicable.

08:08 EDT CPI Aerostructures to restate FY20 financial statements

08:07 EDT Intercept appoints Andrew Saik as CFO - Intercept Pharmaceuticals (ICPT) announced the appointment of Andrew Saik as CFO. He was previously CFO of Vyne Therapeutics (VYNE), where he led a buildout of the company's finance department in the U.S., renegotiated debt obligations to provide the company with enhanced financial flexibility, and helped raise over $135M to fund operations.

08:07 EDT Dine Brands partners with FlyBuy to improve restaurant pickup, delivery - Flybuy Pickup announced its new partnership with Dine Brands Global. Flybuy Pickups innovative, location-based pickup solution will roll out at Applebee's and IHOP restaurants nationwide by the end of 2021. "Dine Brands is leveraging Flybuy Pickup to help improve carside and in-restaurant pickup and delivery. This new technology has proven to reduce guest and driver wait times, maintain food freshness and remove friction in the pickup process for both guests and team members," the company said. "Flybuy will be integrated directly into the Applebee's and IHOP mobile and online ordering experiences. Guests simply place their orders through their mobile apps or on the brands' websites, then drive to pick up their meals with no further action required. Meanwhile, the restaurant receives guest or delivery driver location updates and estimated time of arrival. Each order is fulfilled and prioritized based on the guest's or delivery driver's arrival time, enabling a smooth, fast and efficient handoff immediately upon arrival," the company added.

08:06 EDT Takeda presented results from a new subgroup analysis of SOT recipients - Takeda Pharmaceutical the American Transplant Congress 021 Virtual Connect presented results from a new subgroup analysis of SOT recipients in the Phase 3 TAK-620-303 rial, for the investigational drug TAK-620 (maribavir). More than twice (55.6%, 79/142) as many SOT recipients with R/R CMV infection at baseline treated with maribavir achieved confirmed CMV viremia clearance at Study Week 8 (end of treatment phase) compared to those treated with conventional antiviral therapies (26.1%, 18/69) (investigator assigned treatment; IAT consists of one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir) (adjusted difference [95% CI]: 30.5% [17.3, 43.6]).1 The results presented showed consistent efficacy in SOT recipients receiving maribavir in heart, lung and kidney transplants.

08:06 EDT Allakos completes patient enrollment in Phase 3 study of lirentelimab - Allakos announced that it has completed enrollment in its Phase 3 study of lirentelimab in patients with eosinophilic gastritis and/or eosinophilic duodenitis, and its Phase 2/3 study of lirentelimab in patients with eosinophilic esophagitis. Clinical trial results from both randomized, double-blind, placebo-controlled studies are expected in the fourth quarter of 2021.

08:03 EDT Inari Medical announces late-breaking CLOUT registry data - Inari Medical announced strongly positive interim results of the first 250 deep vein thrombosis patients enrolled in the ClotTriever Outcomes Registry. This latest data showed that ClotTriever removed 100% of the blood clots in the majority of DVT patients without the need for thrombolytic drugs in short single-session procedures. The late-breaking data was presented virtually at NCVH 2021 by principal investigator, Robert Beasley, MD, an interventional radiologist at Palm Vascular Center in Miami, FL. "CLOUT has shown us that by getting between the vessel wall and the thrombus, ClotTriever can remove all of the clot without any injury to the vein or its valves, restoring normal blood flow and valve function," said Dr. Beasley. "For patients with acute, subacute, and chronic clot, ClotTriever has offered long-term relief from the pain associated with DVT and a return to normal life, free from the debilitating symptoms of post-thrombotic syndrome." Use of thrombolytics was completely avoided in all 250 patients across the 24 registry sites and median blood loss was a modest 50ml with a short median thrombectomy procedure time of 28 minutes.

08:03 EDT Bluebird Bio announces FDA lift of clinical hold on HGB-206, HGB-210 studies - Bluebird Bio announced that the FDA has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease, or SCD, gene therapy for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 and Northstar-3 studies of betibeglogene autotemcel gene therapy for adult, adolescent and pediatric patients with transfusion-dependent beta-thalassemia, or TDT. The company is working closely with study investigators and clinical trial sites to resume all study activities as soon as possible. "Patient safety continues to be our utmost priority, and we are grateful for the close partnership with the FDA, investigators, scientists and most importantly, patients, who all contributed to the assessments of the adverse events in HGB-206 that ultimately led to today's announcement," said Andrew Obenshain, president, severe genetic diseases, bluebird bio. "As pioneers in gene therapy, we remain committed to advancing the field through our learnings. Over the past four months, we have gained deeper knowledge and understanding of the pathophysiology of sickle cell disease that will allow us to better serve patients and the broader community. We look forward to resuming our clinical programs and continuing to advance toward major regulatory submissions for sickle cell disease and beta-thalassemia."

08:02 EDT Delcath Systems reports preliminary results from FOCUS trial - Delcath Systems announced an oral presentation of positive preliminary efficacy results from its FOCUS Phase III trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma at the American Society of Clinical Oncology Annual Meeting being held virtually June 4-8, 2021. The oral presentation by Dr. Jonathan Zager, Director of Regional Therapies and Chief Academic Officer, Moffitt Cancer Center; Professor and Chair, Department of Oncologic Sciences, USF Morsani College of Medicine, presented previously announced preliminary data based on 79 of 91 treated HEPZATO patients. Patient level response data were also presented for this same patient set, indicating that 44% of evaluable patients in the HEPZATO arm had a 30% or greater reduction in target tumor lesions at one or more time points versus 17% for patients enrolled in the Best Alternative Care arm. Dr. Sapna Patel, Associate Professor and Uveal Melanoma Program Director, Department of Melanoma Medical Oncology, MD Anderson Cancer Center, the discussant for the session, provided valuable perspective regarding both the efficacy and safety preliminary results. HEPZATO is being studied in the FOCUS trial which is a single-arm, multi-center, open-label trial to treat patients with hepatic-dominant metastatic ocular melanoma. The FOCUS Trial is being conducted at approximately 30 sites in the United States and Europe. The primary endpoint of the FOCUS Trial is Objective Response Rate as measured by RECISTv1.1, in the Intent to Treat population. The single arm trial was powered to demonstrate a superior ORR versus checkpoint inhibitors, one of the few mOM treatment categories with a significant amount of peer reviewed publications. The checkpoint inhibitor ORR was calculated based on a meta-analysis covering 16 different publications which included 476 patients. The pooled overall response rate was 5.5%. To achieve statistical significance at a 95% Confidence Interval the lower bound of the ORR for HEPZATO is required to exceed the 8.3% upper bound of the meta-analysis. Secondary endpoints include Duration of Response, Disease Control Rate, Overall Survival, and Progression-Free Survival. Additional exploratory outcome measures include time to objective response, hepatic progression-free survival, hepatic objective response, and quality of life, safety, and other pharmacokinetic measures. Initially, the trial was a randomized controlled trial which was amended to a single arm trial given slow enrollment due to the rarity of ocular melanoma, absence of crossover to the experimental trial arm, competing clinical trials and the commercial availability of CHEMOSAT in Europe. Included in the prespecified analyses are comparisons against the Best Alternative Care arm which enrolled 32 patients prior to the amendment to a single-arm trial. On March 31, 2021 Delcath released a preliminary analysis of the FOCUS trial data using prespecified analyses based on a data cut on March 12, 2021 which included 87% of treated patients. An Independent Review Committee assessed an ORR of 29.2% in the ITT population, the lower bound of which exceeded the upper bound of the predefined success criteria for the primary ORR endpoint. In the per protocol populations, evaluable patients in the HEPZATO arm had a statistically significant improvement over BAC in prespecified endpoints including: ORR of 32.9% versus 13.8% for the BAC arm, Median PFS of 9.0 months versus 3.1 months for the BAC arm, and DCR of 70.9% versus 37.9% for the BAC arm. In this preliminary analysis, DOR and OS were not yet evaluable. Since not all patients were evaluable for all time points, these preliminary analyses may change as data matures. In the HEPZATO safety population of 94 patients, 38 patients experienced a treatment-emergent serious adverse event. The most commonly reported treatment-emergent serious adverse events were thrombocytopenia, neutropenia, and leukopenia, which were well-manageable. 5% of patients experienced treatment-emergent serious cardiac adverse events. In all cases the events resolved with no ongoing complications. There were no treatment-related deaths in the trial.

08:01 EDT IM Cannabis announces supply agreement with Canada's Flowr - IM Cannabis is pleased to announce that Focus Medical Herbs has signed a multi-year supply agreement with The Flowr Corporation Under the terms of the three-year supply agreement (the "Supply Agreement" and subject to fulfilling applicable regulatory and import requirements, Focus Medical will import Flowr's ultra-premium cannabis strains into Israel. The first shipment is expected to be available in the Israeli market in H2, 2021. Flowr is an established leader in Canada's premium dry flower market. This new partnership with Flowr strengthens and further contributes to IMC's new indoor ultra-premium product category under the IMC brand.

07:57 EDT Nutrien to increase potash production by half a million tons in second half - Nutrien announced that it expects to increase potash production by approximately half a million tons in the second half of 2021 compared to earlier expectations, in response to tightening global potash market conditions. Nutrien has a network of six potash mines with competitively positioned, available capacity that it can utilize to help supply global demand. Domestic and offshore potash sales volumes are currently fully committed through September, based on our original production profile for 2021. Nutrien will be actively hiring additional employees and adapting its resources to help increase production across most of its potash mines, ramping up its Vanscoy facility in particular, and will ensure the highest safety standards are maintained in the process. Nutrien expects these actions to result in upward revisions to potash-related guidance for the second half of 2021 from both a volume and EBITDA perspective, which will be addressed in Q2 results. Nutrien continues to actively monitor the market and evaluate other potential options to further increase production if demand warrants it and may provide additional information in this regard at a later date.

07:56 EDT Salarius Pharmaceuticals presents research data on seclidemstat - Salarius Pharmaceuticals presented key findings from clinical research involving its lead drug candidate, seclidemstat. These results, disclosed in poster presentations at the American Society of Clinical Oncology Virtual Annual Meeting, included data on seclidemstat's safety, dosing and early efficacy signals in patients with Ewing sarcoma, a rare pediatric bone cancer, and other solid tumors, including FET-rearranged sarcomas. The ASCO Annual Meeting is taking place June 4-8, 2021. Seclidemstat is a novel, oral, reversible inhibitor of the lysine-specific histone demethylase 1, an enzyme that has been shown to play a key role in the development and progression of several cancers. In summary, data presented for the first time during ASCO demonstrated that seclidemstat has a manageable safety profile, favorable pharmacokinetics that support twice-daily oral dosing, and showed evidence of anti-tumor activity in an advanced, heavily pre-treated patient population. In addition, seclidemstat showed no significant hematological toxicities, which can be a limitation for other LSD1 inhibitors. Importantly, single-agent seclidemstat treatment showed signs of drug activity in patients with relapsed/refractory Ewing sarcoma and other advanced cancers, including FET-rearranged sarcomas, also referred to as Ewing-related sarcomas. In patients with FET-rearranged sarcomas, seclidemstat treatment resulted in stable disease and prolonged time to progression suggestive of disease control, a clinically relevant endpoint for soft tissue sarcomas. Poster Title: Phase 1 trial of seclidemstat in patients with relapsed/refractory Ewing sarcoma. Key Information & Findings: For the first time, Salarius is discussing the full findings from the dose-expansion stage of the Phase 1/2, open label study of single-agent seclidemstat in patients with elapsed/refractory Ewing sarcoma. Seclidemstat demonstrated a manageable safety profile with proof-of-concept preliminary activity at or below the recommended Phase 2 dose, established as 900 mg BID. In this heavily pretreated population, a patient dosed at 600 mg BID achieved a reduction in three target lesions after 58 days with further tumor shrinkage after 112 days and 168 days for a maximum 76% tumor shrinkage despite overall progressive disease; Two additional patients dosed at 600 mg BID and 900 mg BID for 56 days demonstrated overall stable disease; Seclidemstat's safety profile is predominantly GI-related with no treatment-related deaths and no significant hematological treatment-related adverse events; Study results warrant further study of seclidemstat in Ewing sarcoma combined with chemotherapy. Poster Title: Preliminary efficacy from an ongoing Phase 1 dose escalation of seclidemstat in patients with advanced solid tumors. Key Information & Findings: This is an ongoing Phase 1/2 open-label, dose-escalation trial assessing single-agent seclidemstat in advanced or recurrent solid tumors. As of April 13, 2021, seclidemstat demonstrated initial activity among advanced sarcoma patients with a manageable safety profile. 7 patients treated for ovarian cancer, prostate cancer and sarcomas achieved stable disease after 56 days with median time to progressionof 4.3 months; patients with advanced FET-rearranged sarcomas demonstrated prolonged SD and prolonged TTP suggestive of disease control, a clinically relevant endpoint for soft tissue sarcoma; As of April 13, 2021, 3 FET-rearranged sarcoma patients demonstrated TTP of 9.4 months, 7.2 months and 4.3 months, respectively; Among 3 patients with FET-translocated sarcomas, prolonged SD greater than 6 months was observed in 2 patients; An elderly patient treated for metastatic extra skeletal myxoid chondrosarcoma, with an aggressive TAF15-CHN translocation, who demonstrated overall SD for 9.4 months has continued therapy and has now been treated for 11 cycles; All 3 FET-translocated patients enrolled in the study showed a TTP that suggests single-agent activity based on a benchmark used to assess novel agent activity for advanced soft tissue sarcomas; Preliminary clinical data supports further exploration in FET-translocated sarcomas, or Ewing-related sarcomas, as a single agent and in a combination therapy. Poster Title: Phase 1 expansion trial of the LSD1 inhibitor seclidemstat with and without topotecan and cyclophosphamide in patients with relapsed or refractory: Key Information: This is an ongoing dose-expansion study assessing seclidemstat at the RP2D in two patient cohorts: a single-agent expansion in select sarcoma patients and a safety lead-in dose escalation and expansion of seclidemstat in combination with the chemotherapy agents topotecan and cyclophosphamide in Ewing sarcoma patients. The sarcoma cohort will enroll patients with myxoid liposarcoma or other select sarcomas with FET family translocations, including desmoplastic small round cell tumor; the trial will enroll patients treated with one to three prior lines of therapy; The Ewing sarcoma cohort will allow patients treated with up to two prior lines of therapy; Primary objective is safety and tolerability, and secondary objective is efficacy; Recruiting patients across eight U.S. locations

07:52 EDT Translate Bio achieves milestone related to influenza mRNA vaccine program - Translate Bio (TBIO) announced it has achieved a manufacturing milestone under the collaboration with Sanofi Pasteur related to its influenza mRNA vaccine program. Translate Bio will receive a $50 million payment from Sanofi Pasteur (SNY) for the successful manufacture, release, and delivery of clinical drug product to supply Sanofi Pasteur's Phase 1 influenza clinical trial which is anticipated to begin in the coming weeks. The Phase 1 clinical trial will evaluate a monovalent influenza vaccine candidate and will inform the next steps of the mRNA-based influenza vaccine program.

07:50 EDT Digihost Technology launches DigiGreen Initiative - Digihost Technology is pleased to announce the launch of its new DigiGreen Initiative, an industry leading plan to reduce the Company's already low carbon footprint. In addition to achieving technological and economic excellence, since inception, the Company has focused on being a good corporate citizen and operating its business in an environmentally and socially responsible way. As part of this mandate, the Company located its cryptocurrency mining farm in Upstate New York to take advantage of the low carbon emission energy profile of that area. The Company believes that more can be done to further reduce its carbon footprint, while maintaining its industry leading efficient cryptocurrency mining operations, and is therefore pleased to share with the marketplace information on the new DigiGreen Initiative. DigiGreen Initiative will focus on four immediate steps designed to create sustainable, environmentally and economically sound in-house practices, which will distinguish the Company as an industry leader in maintaining profitability, while lowering or eliminating its carbon footprint: a. Corporate Leadership: Recognizing the need for top-down leadership, the Company has commenced a search for a Chief Renewable Energy Officer. The CREO will report directly to the CEO and the President of the Company and help to advise the Board of Directors on the progress of short-term goals and the development of a sustainable long-term renewable energy plan. The CREO will also be responsible for creating and supporting dynamic educational outreach programs with research institutions to test, prove-out, and onboard future fuel technology options; Engage in "Bridge" and Renewable Energy Sources: Digihost previously reported in a press release that over 90% of the energy currently consumed by the Company in its Bitcoin mining operations is from sources that create zero carbon emissions and more than 50% of the energy consumed by the Company is generated from renewable sources. As the Company intends to purchase and bring online its own power generation facilities, it will focus on powering these facilities using "bridge" power sources, meaning low-carbon, or renewable sources of energy where available. For example, sourcing renewable natural gas, a natural gas developed from the collection and conditioning of organic waste, lowers carbon not just at the point of use but across the entire system, removing waste that would otherwise sit in fields or in landfills. The end result is a fuel that is lower-carbon than natural gas, requires no infrastructure redevelopment in plants already designed for natural gas, and removes a large source of carbon from the environment. The CREO will be responsible for sourcing RNG for the Company's North Tonawanda facility, as well as designing 100% renewable energy strategies for powering North Tonawanda as well as new power facilities to be acquired by the Company; Develop In-House Standards of Measuring Climate Impact: Initial research has already commenced on developing proprietary standards for measuring the Company's carbon impact. The CREO, in conjunction with the CEO and the President, will be empowered to use this standard as an environmental audit tool for the various operating units of Digihost, to generate accountability reports, and to advise Directors and Shareholders on efforts to minimize the Company's the carbon footprint. We believe this standard will eventually become an industry standard and provide a template for industry colleagues, regulators, and others to better understand the climate impact of blockchain technology moving forward; and Explore Alternative Ways to Reduce Overall Carbon Footprint: In the short-term, DigiGreen Initiative will focus internally, creating best practices standards and securing bridge and renewable energy sources to reduce the Company's already low carbon footprint. Long-term goals will incorporate a broader view of improving the geographic areas that the Company operates in and the sector as a whole, and the CREO will explore new ways to achieve these goals by: Exploring green space initiatives to improve the communities that the Company operates in and create offsets as we lower our overall carbon footprint, helping to ensure and protect green space and resources; Partnering with research institutions, to pioneer, develop, and implement new renewable fuel options, such as hydrogen power, to bring these technologies to market sooner; and Collaborating with industry colleagues to maximize the positive impact companies can have as a whole, while also helping to establish guidelines, standards, and best practices for new market entrants.

07:48 EDT Pembina reinforces proposal, reviews benefits for Inter Pipeline - Pembina Pipeline (PBA) reinforced its view of the substantial value opportunity for shareholders of Inter Pipeline (IPPLF) through the board-supported strategic combination with Pembina. "Pembina also cautioned Inter Pipeline shareholders not to tender their shares to Brookfield Infrastructure Partners' (BIP) opportunistic, hostile offer that would deny them the significant potential upside of a combined company," the company said. Under the Strategic Combination, Inter Pipeline shareholders will receive 0.5 shares of Pembina for each share of Inter Pipeline. This represents value of $19.45 per share, or a 45% premium to the unaffected price of Inter Pipeline shares, based on the closing price of Pembina's common shares on May 31, 2021. Pembina Pipeline noted, "Inter Pipeline shareholders stand to realize significant benefits and upside value from the Strategic Combination... Immediate Dividend Increase: Upon closing, Inter Pipeline shareholders will benefit from an immediate 175% increase to their monthly dividend, compared to their current monthly dividend of 4c per Inter Pipeline share. Furthermore, Pembina intends to increase its monthly common share dividend by an additional 1c per share, to 23c per share following the successful commissioning and in-service of the Heartland Petrochemical Complex. By comparison, Inter Pipeline shareholders who elect to receive class A exchangeable shares of Brookfield Infrastructure Corporation will see only a modest 15% increase in their per share dividend... Synergies: Inter Pipeline shareholders will share in the $150M-$200M of anticipated near-term annual synergies...Tax-Free Rollover for Taxable Canadian Shareholders: The Strategic Combination will allow for a fully tax deferred rollover of Inter Pipeline shares into Pembina shares for Canadian resident shareholders... High Degree of Regulatory Certainty: Pembina has committed to secure all regulatory approvals, including obtaining approval under the Competition Act, as soon as possible...Pembina has refined its estimate for closing of the Strategic Combination to late-Q3 / early-Q4 of 2021."

07:46 EDT Moderna files for a CMA for its Covid-19 EU vaccine in adolescents - Moderna announced that it has submitted for a conditional marketing approval for its COVID-19 vaccine in adolescents with the European Medicines Agency . "We are pleased to announce that we have submitted for conditional marketing approval of our COVID-19 vaccine with the European Medicines Agency for use in adolescents in the European Union," said Stephane Bancel, Chief Executive Officer of Moderna. "We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection in adolescents. We have filed for authorization with Health Canada and we will file for an Emergency Use Authorization with the U.S. FDA and regulatory agencies around the world for this important younger age population. We remain committed to doing our part to help end the COVID-19 pandemic." In May, the Company announced that the Phase 2/3 TeenCOVE study of Moderna's COVID-19 vaccine in adolescents met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition. The vaccine efficacy in the nearly 2,500 adolescents who received the Moderna COVID-19 vaccine was observed to be 100% when using the same case definition as in the Phase 3 COVE study in adults. In addition, a vaccine efficacy of 93% in seronegative participants was observed starting 14 days after the first dose using the secondary Centers for Disease Control and Prevention case definition of COVID-19, which tested for milder disease. The study enrolled 3,732 participants ages 12 to less than 18 years in the U.S.

07:45 EDT 1Life Healthcare to acquire Iora Health in $2.1B all-stock transaction - 1Life Healthcare announced it has entered into a definitive agreement to acquire Iora Health, a human-centric, value-based primary care group with built-for-purpose technology focused on serving Medicare populations, in an all-stock transaction valued at approximately $2.1 billion. One Medical and Iora Health are aligned in their missions, models, and cultures to transform healthcare for key stakeholders -- Consumers, Employers and Payers, Providers, and Health Networks. Together, the two companies can further accelerate and build upon their impacts for these stakeholders, while simultaneously expanding their models in existing markets, entering new markets, serving new populations, expanding full-risk models, and leveraging their purpose-built technologies for increased growth and scale. Strategic and financial benefits of the transaction include: Creates a premier national member-based, technology-powered primary care platform to deliver better health, better care, and lower costs across Commercial and Medicare populations; Positions One Medical with Iora Health to advance the health of members across every stage of life; Extends One Medical's platform to deliver multi-modal care with 24/7 national digital health and in-person care across a combined 28 markets and beyond; Expands potential market opportunity to $870 billion across Commercial and Medicare segments, including the new Medicare Direct Contracting program; Enhances One Medical's risk-taking capabilities and extends One Medical into full-risk Medicare reimbursement models; Amplifies the power of purpose-built technologies to deliver premier member experiences, population health, provider support, and value-based care across every stage of life; Accelerates the expansion of two high-growth organizations, with complementary cultures and models serving as a premier place to practice modernized healthcare; and, Offers an opportunity to create significant value, with an expected $350+ million in annual revenue synergies by 2025, ~$30 million in annual net cost synergies by 2025, and with ~$30 million in cumulative capex savings through 2025. A designee of Iora Health will join the One Medical Board and Rushika Fernandopulle will become One Medical's Chief Innovation Officer. Under the terms of the agreement, Iora Health shareholders will receive 56.1 million shares of One Medical common stock. Based on the closing share price of One Medical's common stock of $35.59 on June 4th, 2021, the total transaction is valued at approximately $2.1 billion. Upon completion of the transaction, Iora Health shareholders are expected to own approximately 26.75% of the combined company. The transaction is expected to close in late Q3 or Q4 of 2021 and is subject to customary closing conditions, including approval by One Medical and Iora Health stockholders and receipt of regulatory approval.

07:41 EDT EbixCash appoints S Ravi to board of directors - EbixCash Private announced the appointment of Mr. S Ravi, as a new independent director to the EbixCash Board.Ravi is presently serving as the Chairman and Director of Tourism Finance Corporation of India Ltd. - the premier government owned financial Institution, set-up to promote tourism in India. He also presently serves on the boards of Aditya Birla Health Insurance Company Ltd., Star Union Dai-ichi Life Insurance Company Ltd., Aditya Birla ARC Ltd., IIFL Asset Management Ltd. and SBI Payment Services Pvt. Ltd.

07:39 EDT OpGen submits updated 510(k) summary to FDA, completes move to Maryland - OpGen announced that it has submitted an updated 510(k) summary document to the U.S. FDA for its Acuitas AMR Gene Panel for Isolates. This document incorporates all of the FDA's requested updates to various key documents such as the Package Insert, Electronic User Guide, and Operator Manual. Consistent with the FDA's previously communicated timeline, the FDA provided substantive feedback on all of these key documents by the end of May. The FDA previously informed OpGen that it intends to complete its review by the end of August 2021, but that it cannot commit to a timeline and that such timeline can be affected by various factors, including the FDA's other workload and public health priorities. OpGen recently also completed the move of its U.S. headquarters, laboratories and operations as well as warehouse to its new Rockville, Maryland based facility. The Company plans to register this newly built-out facility with the FDA and other relevant authorities for the future business operations in the U.S. The new 10,000 square feet facility marks the completion of the business integration and will result in net savings of approximately $600 thousand annually in the coming years in terms of operating efficiencies and reduced rent. Given recent new Unyvero installations in Q1 and 2021 year-to-date as well as anticipated strong demand for additional Unyvero system placements in the upcoming quarters, OpGen has also ordered an additional 30 Unyvero Analyzers from its Curetis subsidiary and will be moving these into its U.S. warehouse facilities in the coming weeks. Going forward, all Unyvero cartridges as well as Acuitas consumables will be stocked and shipped directly from the new Rockville based facility.

07:36 EDT Microbot Medical appoints Giora Weisz to Scientific Advisory Board - Microbot Medical announces Giora Weisz, MD joined the Company's Scientific Advisory Board. Dr. Weisz is a practicing interventional cardiologist and clinical researcher who has pioneered novel robotic-enhanced coronary interventions, as well as navigation and positioning technologies. His areas of expertise include cardiac catheterization, coronary artery disease and diagnostic angiography, which make his assistance an invaluable asset to Microbot as it continues to develop the LIBERTY Robotic System. Weisz is an Associate Professor of Medicine at Columbia University Medical Center, Director of Interventional Cardiology at the New York-Presbyterian Hudson Valley Hospital, and a member of the faculty of the Center of Interventional Vascular Therapy at Columbia University Medical Center.

07:34 EDT View Inc. set to join Russell 3000 Index - View, Inc. is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28 according to a preliminary list of additions posted June 4.

07:32 EDT Amryt Pharma says Oleogel-S10 NDA will not require advisory committee meeting - Amryt announces that the U.S. Food and Drug Administration has confirmed that Amryt's New Drug Application for Oleogel-S10 for the treatment of Epidermolysis Bullosa ("EB") will not require an Advisory Committee meeting. Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment.

07:30 EDT Concrete Pumping reschedules Q2 conference call - The reschedule is being driven by the Company's continuing evaluation of the accounting treatment for its warrants in light of the SEC Warrant Accounting Statement. On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a public statement on accounting and reporting considerations for warrants issued by special purpose acquisition companies. The SEC Warrant Accounting Statement discussed "certain features of warrants issued in SPAC transactions" that "may be common across many entities." The SEC Warrant Accounting Statement indicated that when one or more of such features is included in a warrant, the warrant "should be classified as a liability measured at fair value, with changes in fair value each period reported in earnings." The Company is currently finalizing its accounting analysis for the Warrants. While the conclusion to classify its warrants as liabilities instead of equity would impact the Company's net income, the change would be a non-cash adjustment that would be excluded from the calculation of Adjusted EBITDA. As such, any impact from this analysis is not expected to impact the above preliminary results. The new conference call information has been provided below. Date: Monday, June 14, 2021, Time: 5:00 p.m. Eastern time.

07:27 EDT MediWound announces peer-reviewed paper on basal cell carcinoma - MediWound announced that a peer-reviewed publication of a case series report of basal cell carcinoma destruction by a concentrate of proteolytic enzymes enriched in bromelain has been published in the Open Dermatology Journal. MediWound anticipates initiating a phase I/II clinical study of MW005 for the treatment of BCC this month, with data expected by the end of 2021. The paper, entitled Basal Cell Carcinoma Destruction by a Concentrate of Proteolytic Enzymes Enriched in Bromelain: A Preliminary Report, details case series experience using a concentrate of proteolytic enzymes enriched in bromelain for the destruction of six BCC tumors. Six BCCs located on the face, neck, and extremities were self-treated by three patients with 2-6 applications. All of the BCCs were completely removed and two of the lesion's sites were surgically excised after 6 months with no tumor cells noted on histopathology. None of the BCCs recurred over the subsequent year. The findings provide a preliminary proof-of-concept that a concentrate of proteolytic enzymes enriched in bromelain may be a safe and effective destructive treatment for basal cell carcinomas. BCC is a non-melanoma skin cancer that arises from the basal layer of epidermis and its appendages. According to the American Cancer Society, BCC is the most diagnosed skin cancer in the United States with approximately 4.3 million diagnosed cases every year. The increasing number of diagnosed BCC is a result of better skin cancer detection, increased sun exposure, and greater life expectancy.

07:25 EDT 4D Molecular appoints Carolyne Zimmerman as CBO - 4D Molecular Therapeutics (FDMT) announced the appointment of Carolyne Zimmermann as Chief Business Officer. Ms. Zimmermann joins 4DMT from Johnson & Johnson Innovation (JNJ) where she served as Vice President, Transactions.

07:23 EDT Red White & Bloom Brands closes $44.5M in financing - Red White & Bloom Brands is pleased to announce the completion of certain financing transactions that provide for approximately $36.8 of new cash and the retirement of $7.7M of debt. The Company previously closed a non-brokered "units for debt" private placement of 8,445,426 units at a price of CDN $1.15 per Unit for gross proceeds of CAD $9,712,239. Each Unit consists of one Series II Convertible Preferred Share of RWB and one half of one common share purchase warrant. Each Warrant is exercisable to acquire one additional common share at a price of CDN $1.15 per RWB Share until May 12, 2023. In addition to the statutory 4-month hold, the investors have agreed to a 12 month lock up of their shares. In addition, RWB completed a private placement to an arm's length purchaser of a principal amount US $6,500,000 unsecured debenture. The Debenture bears interest at the rate of 12% per annum and matures 150 days from the date of issuance. As consideration for the purchase of the Debenture by the Purchaser, RWB paid the Purchaser an origination fee by way of the issuance of 531,000 RWB Shares. The gross proceeds of the Debenture will be used by RWB for working capital purposes. In addition, on June 4, 2021, RWB's wholly-owned subsidiary, RWB Florida LLC, a Delaware limited liability company entered into agreements for an aggregate capital raise of US $30,234,224. The raise includes an investment of US $11,337,834 from certain strategic investors directly into RWB Florida. Under the terms of the Investment Transaction, the Investors shall receive a direct equity stake in RWB Florida in the form of Class B membership interests in the aggregate of 17.70% of the Company's outstanding interests. Concurrently with the Investment Transaction, the Investors have advanced an aggregate of US $18,896,390 in subordinated debt to RWB Florida at an 8% interest rate due in 36 months. The Debt is subordinated to existing debt, secured by an assignment of certain collateral interests, is guaranteed by RWB and, at the option of the holder, is convertible into RWB Shares at a price of US$2.75. In addition, the investors have a 5 day option to invest a further approximately US$4 million on substantially the same terms.

07:18 EDT Paya Holdings announces proposed debt refinancing - Paya Holdings announced plans to refinance its outstanding $228 million term loan facility due 2027 and $25 million revolving credit facility due 2025. The Company anticipates refinancing the facilities with the proceeds of a new seven-year $250 million term loan and a five-year $45 million revolving credit facility expected to be undrawn at closing. The objectives of the refinancing are to increase the Company's financial flexibility, reduce interest expense and extend its debt maturity. The terms of the proposed refinancing will be disclosed upon the completion of the transaction, which is expected to occur in late June or early July. The proposed refinancing is subject to ongoing negotiation of definitive documentation for the term loan and revolving credit facilities as well as market conditions. There can be no assurances that the refinancing will occur, or, if it does, the terms of the refinancing.

07:18 EDT Ur-Energy to join Russell 3000 Index - Ur-Energy is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, according to a preliminary list of additions made public June 4.

07:16 EDT Aurinia Pharmaceuticals presents AURORA 1 study data at ERA-EDTA congress - Aurinia Pharmaceuticals presented an analysis of its Phase 3 AURORA 1 study data at the European Renal Association - European Dialysis and Transplant Association, or ERA-EDTA congress. The presentation follows the recent introduction of new data from an interim analysis of the AURORA 2 continuation study at the European Alliance of Associations for Rheumatology Congress. In the assessment presented at ERA-EDTA, researchers conducted a sensitivity study evaluating renal response, or RR, with additional urine protein creatinine ratio, or UPCR, targets given the efficacy demonstrated of voclosporin in terms of proteinuria reduction in the AURORA 1 study. This examination demonstrated that patients treated with voclosporin in addition to mycophenolate mofetil, or MMF, and low-dose steroids achieved statistically significant increased renal response rates regardless of the level of UPCR, including at an even more stringent 0.3 mg/mg target. The data further support the efficacy and safety observed with voclosporin in the Phase 3 AURORA 1 trial. The ERA-EDTA assessment of Aurinia's Phase 3 AURORA 1 study included a total of 179 participants in the voclosporin arm and 178 participants in the control arm from the AURORA 1 trial. All participants received MMF and low-dose oral steroids. The UPCR component of RR was revised to include UPCR targets at 0.2 mg/mg intervals above and below the original 0.5 target used for the primary endpoint in AURORA 1. Complete renal response, or CRR, defined as achievement of UPCR 0.5 mg/mg with stable renal function in the presence of sustained, low-dose steroids and no use of rescue medication. Complete renal response analysis at approximately one year included Week 52 data from AURORA 1. Odds ratios for RR at 26 weeks and 52 weeks of treatment were analyzed using a logistic regression model with terms for treatment, baseline UPCR, biopsy class, and MMF use at baseline and region. In the AURORA 1 trial, Lupkynis was well tolerated with no unexpected safety signals. Serious adverse events, or SAEs, were reported in 21% of those treated with Lupkynis and in 21% of those in the control group. Infection and infestations were the most commonly reported SAEs, in 10% of the Lupkynis group and 11% of the control group. Overall mortality in the AURORA 1 trial was low, with six deaths observed; one in the LUPKYNIS group and five in the control group. Additionally, the Lupkynis group showed no notable decrease at Week 52 in mean eGFR or increase in mean blood pressure, lipids or glucose, which are common adverse events associated with traditional calcineurin inhibitors, or CNIs.

07:12 EDT RedHill Biopharma completes enrollment of oral opaganib phase 2/3 COVID-19 study - RedHill Biopharma announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib in patients hospitalized with severe COVID-19 pneumonia. A total of 475 patients were randomized, more than the planned 464. The primary endpoint of the study is the proportion of patients breathing room air without oxygen support by Day 14. The study captures additional important outcome measures in the follow up period of up to 6 weeks, such as the time to hospital discharge, improvement according to the World Health Organization Ordinal Scale for Clinical Improvement and incidence of intubation and mortality. An evaluation of the blinded blended intubation and mortality rates to date is encouraging as compared to reported rates of mortality from large platform studies such as RECOVERY, and other studies in similar patient populations. Furthermore, four independent DSMB recommendations to continue the study were already provided following unblinded safety and futility reviews. In addition to ongoing discussions with the FDA and other regulators, the company has also met with the EMA to talk about a European pathway. As with all discussions with regulatory bodies, next steps will be guided by study results. Discussions are also ongoing with potential partners who are interested in the rights to opaganib in various countries.

07:10 EDT Lexaria issues progress report on first human clinical study - Lexaria Bioscience is pleased to report that treatment and dosing in its human clinical study have been completed ahead of schedule. HYPER-H21-1 focused on testing DehydraTECH-enabled cannabidiol for potential use as a hypertension treatment alternative. Twenty-four human volunteers aged 45 to 65 were dosed within this study, all of whom tolerated treatment well with no serious adverse events or side effects observed or reported. "Completing this work in the midst of the COVID-19 pandemic was challenging and we acknowledge and commend the dedication and work ethic of our Europe-based research partners and all parties involved," said Chris Bunka, CEO of Lexaria. "Blood samples from the study volunteers will be shipped this week to our U.S. and Canadian analytical testing laboratory partners, and we expect to complete all sample and data analyses and reporting ahead of schedule, by July or August instead of the end of Q3 as previously indicated."

07:10 EDT Lightspeed POS to acquire NuORDER for $212.5M in cash, $212.5M in shares - Lightspeed (LSPD) announced it has entered into definitive agreements to acquire two global leaders in digital commerce. Following the strong initial reception and success of the Lightspeed Supplier Network, Lightspeed has announced it has entered into a definitive agreement to acquire NuORDER, a digital platform connecting businesses and suppliers. "Together, Lightspeed and NuORDER will create an industry-leading bridge between the merchant and supplier experience, simplifying product ordering for retailers and offering brands crucial insight into how their products move. The acquisition will capitalize on the early success of the Lightspeed Supplier Network and accelerate the growth of Lightspeed's financial services offerings, including Lightspeed Payments and Lightspeed Capital, while establishing the company as a global distribution network for leading brands," the company added. NuORDER currently serves over 3,000 brands and saw more than 100,000 retailers make more than $11.5B in orders through its platform in the trailing twelve month period ended March 31, 2021. Lightspeed will acquire NuORDER for total estimated consideration of approximately $425M, satisfied by way of payment on closing of approximately $212.5M in cash and the issuance of subordinate voting shares in the capital of Lightspeed valued at approximately $212.5M. The deal, which is subject to customary closing conditions and post-closing working capital adjustment, is expected to close during the quarter ended September 30, 2021 after the receipt of applicable regulatory approvals.

07:07 EDT Ring Energy executes targeted hedging transactions to increase FCF generation - Ring Energy provided an update on its derivate positions for 2021 and 2022 as it opportunistically responds to an improved crude oil price environment. Key Changes to Hedge Book: Bought back a 1,500 barrels of oil per day call option for June 1 through December 31, 2021, and entered into an approximate 879 Bbls/d calendar 2022 swap contract for no net cost; Anticipate more than 320,000 barrels of crude oil sales for June 1 through December 31, 2021, to be realized at a higher level than the $55.35 per barrel ceiling price previously in place; Additionally, the 2022 swap position is priced higher than the $45.66 per barrel collective average price previously in place; and Expected increase to cash flow from higher realized pricing in 2021 will primarily be used to further pay down debt. Paul McKinney, Chairman of the Board and CEO, commented, "When we entered into contracts to substantially fill our hedge book for expected 2021 production in late fall of last year, we were operating in a backdrop of $45 per barrel WTI primarily due to the economic impacts of COVID-19. Moving into our fall bank redetermination process, our hedging strategy was appropriately designed to lock in 2021 pricing that fully funded our targeted work program while guaranteeing the necessary cash flow to pay down debt. Substantially driven by the dramatic improvement in economic activity with the worldwide recovery from COVID-19, there has been an almost 50% increase in WTI crude oil pricing over the past six months. This much-improved price environment has allowed us to pivot to a more opportunistic hedging strategy. The hedging transactions that we recently executed will generate additional free cash flow in 2021, further strengthen our financial and market position, and drive meaningful returns to our shareholders. We remain focused on steadily paying down debt, divesting of non-core assets, and continuously improving our debt-to-EBITDA metrics."

07:06 EDT Comstock Mining set to join Russell Microcap Index - Comstock Mining announced that it is set to join the Russell Microcap Index at the conclusion of the 2021 Russell Microcap Index's annual reconstitution, effective after the US market opens on June 28, 2021, according to the preliminary list of additions posted June 4, 2021.

07:04 EDT Transocean announces agreement with Shipyard to delay delivery of drillships - Transocean Ltd. (RIG) announced that it has agreed with Sembcorp (SMBMF) Marine's subsidiary, Jurong Shipyard Pte, on the delayed delivery of the ultra-deepwater drillships Deepwater Atlas and Deepwater Titan. As part of the agreement, JSPL has agreed to accept deferred payment for both rigs. The Deepwater Atlas and Deepwater Titan are the world's first eighth generation ultra-deepwater drillships and only rigs to feature a 3,000,000 pound hook-load. These drillships are the most capable and highest specification rigs in the world and will include the first 20,000 psi well control system. In addition to their state-of-the-art drilling capabilities, these rigs are also designed and equipped to optimize fuel consumption, reduce emissions, and thus minimize the associated carbon footprint of each offshore project. Deepwater Atlas: Delivery of the drillship is now expected to be in December 2021. Upon delivery, Transocean will make a $50 million payment to JSPL; the balance of payments owed to the shipyard, or approximately $370 million, will be payable during a five-year period following delivery pursuant to a secured financing arrangement with the shipyard. Transocean also has agreed with BOE Exploration & Production that drilling operations on the Shenandoah project in the U.S. Gulf of Mexico are expected to commence during the third quarter of 2022. Transocean expects Beacon to commence drilling on its Shenandoah project utilizing the Deepwater Atlas following a final investment decision from Beacon and its partners. That decision is expected to be made on or before July 31, 2021. Deepwater Titan: Delivery of the drillship is now expected to be in May 2022. Upon delivery, Transocean will pay JSPL 80% of amounts owed, or approximately $350 million. Twenty percent of amounts owed, or approximately $90 million will be deferred and payable over a five-year period following delivery pursuant to a deferred payment arrangement with the shipyard. Transocean also has agreed with Chevron U.S.A. (CVX) that commercial operations of the Deepwater Titan are expected to commence in the first quarter of 2023. Transocean's contract with Chevron maintains its duration and estimated backlog of $830 million, excluding mobilization and reimbursables. Payments under each arrangement will be made in accordance with the respective payment schedules over the terms of each arrangement. Principal balances will carry an interest rate of 4.5% per annum.

07:01 EDT US Concrete trading halted, news dissemination

06:59 EDT Piedmont Office Realty announces completed leasing transactions through May - Piedmont Office Realty Trust announced in advance of the National Association of Real Estate Investment Trusts' Annual Investor Conference which begins on June 8th that it has completed approximately 230,000 square feet of leasing transactions during the Second Quarter of 2021 through May, with approximately 60% related to new tenant leasing. This completed leasing total excludes the progress on the previously-reported 5-year, 313,000 square foot renewal negotiation with the City of New York at 60 Broad Street, which cleared the final stage of the public hearing review process in late May and now awaits execution by the Mayor's office.

06:57 EDT Seabed selects Velodyne Lidar sensors for mobile mapping system - Velodyne Lidar announced Seabed B.V., which specializes in high quality equipment for offshore surveying and dredging, has selected Puck sensors for its lidar mobile mapping system. The Seabed system is a turnkey mobile lidar solution for hydrographic surveys that can support sustainable planning which aims to protect sensitive historic and marine environments. The Seabed lidar system, equipped with a Puck sensor, provides complete above water point cloud data and can operate in harsh maritime conditions. The system conducts 3D data capture of intricate measurements of inshore, nearshore and inland waterways from up to 100 meters away. It is designed to be simple to mobilize and easy to use without the need for specialized training or qualifications, delivering rapid results that can save time and money.

06:55 EDT Merck reports new data on KEYTRUDA plus LENVIMA versus sunitinib - Merck and Eisai announced new investigational data from the pivotal Phase 3 CLEAR/KEYNOTE-581 trial, which evaluated the combinations of KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, and LENVIMA plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma. Results from a new analysis evaluating health-related quality of life (HRQoL) based on patient-reported outcomes are being presented during an oral abstract session at the 2021 American Society of Clinical Oncology Annual Meeting. Data from CLEAR/KEYTNOTE-581 were originally presented at the 2021 Genitourinary Cancers Symposium and published in the New England Journal of Medicine, and data from this trial are currently under review with the U.S. Food and Drug Administration. In an analysis of a secondary endpoint of HRQoL scores in the CLEAR/KEYNOTE-581 trial, KEYTRUDA plus LENVIMA and LENVIMA plus everolimus were evaluated to determine the impact on HRQoL compared to sunitinib in patients with advanced RCC. This was assessed based on patient-reported outcomes using three HRQoL and symptom measures: Functional Assessment of Cancer Therapy Kidney Symptom Index - Disease-Related Symptoms, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer - Core 30 and European Quality of Life Five-Dimensions - 3-Level System, Unless otherwise noted, HRQoL analyses were based on data from randomized patients who received at least one dose of study treatment. No adjustments for multiple testing or estimation were used; p-values and confidence intervals are nominal and descriptive. Longitudinal change from baseline was assessed by mixed model analysis. Least squares mean differences and 95% CI were calculated from baseline. Time to deterioration was assessed using time to first deterioration, which is the number of weeks between randomization and the first deterioration event, and time until definitive deterioration, which is the number of weeks between randomization and the earliest deterioration event with no subsequent recovery above the deterioration threshold or no subsequent HRQoL assessment data. All times to deterioration were calculated and compared using the Kaplan-Meier method, stratified log-rank tests and Cox models. KEYTRUDA plus LENVIMA demonstrated similar changes from baseline at mean follow-up on 14 out of 18 HRQoL and disease-related symptom scores and better HRQoL and disease-related symptom scores for the following measures: physical functioning, fatigue, dyspnea and constipation, as measured by the QLQ-C30, versus sunitinib. LENVIMA plus everolimus demonstrated similar changes from baseline at mean follow-up on 14 out of 18 HRQoL and disease-related symptom scores and worse HRQoL and disease-related symptom scores in the following measures: Global Health Score/QoL, appetite lossand diarrhea compared to sunitinib. KEYTRUDA plus LENVIMA demonstrated a similar TTD in 14 out of 18 HRQoL and disease-related symptom scores, and a delay in TTD for physical functioning, dyspnea, appetite loss, and EQ-5D visual analog scale compared to sunitinib. KEYTRUDA plus LENVIMA demonstrated a delay in TUDD in 16 out of 18 HRQoL and disease-related symptom scores and a similar TUDD for cognitive functioning and financial difficulties compared to sunitinib.

06:51 EDT Bionano Genomics up over 8% in pre-market as top trending ticker on StockTwits - Shares of Bionano Genomics are up another 8.4% at $7.45 in early pre-market trading following Friday's 9% rally. The stock is a top-trending ticker on StockTwits in terms of message volume this morning.

06:46 EDT Flowr enters supply agreement with Focus Medical Herbs, IM Cannabis - The Flowr Corporation (FLWPF) has entered into a supply agreement ("Supply Agreement") with Focus Medical Herbs, a company which IM Cannabis Corp. (IMCC) has an exclusive commercial agreement with in Israel. Pursuant to the terms of the Supply Agreement, a wholly-owned subsidiary of Flowr has agreed to export up to five hundred kilograms of premium dry flower cannabis in bulk form into Israel. The Supply Agreement represents the Company's first significant international distribution agreement and first export opportunity into Israel. The Company expects its first shipment of BC Pink Kush to be available in the Israeli market in H2, 2021. The partnership with Focus Medical is for a period of three years, subject to certain early termination provisions and applicable regulatory requirements including the receipt of import and export permits.

06:42 EDT SpringsWorks, Seagen enter collaboration for nirogacestat w/ SEA-BCMA - SpringWorks Therapeutics (SWTX) announced that the company has entered into a clinical trial collaboration agreement with Seagen (SGEN) to evaluate nirogacestat, SpringWorks' investigational gamma secretase inhibitor, in combination with SEA-BCMA, Seagen's investigational monoclonal antibody targeting B-cell maturation agent, in patients with relapsed or refractory multiple myeloma. Gamma secretase inhibition prevents the cleavage and shedding of BCMA from the surface of myeloma cells. In preclinical models, nirogacestat has been shown to increase levels of membrane-bound BCMA and reduce levels of soluble BCMA, thereby enhancing the activity of BCMA-targeted therapies. Under the terms of the agreement, Seagen will sponsor and conduct the Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the combination, and will assume all costs associated with the study, other than expenses related to the manufacturing of nirogacestat and certain expenses related to intellectual property rights. Seagen and SpringWorks will also form a joint development committee to manage the clinical study, which is expected to commence in the second half of 2021. In addition to its ongoing clinical collaborations with BCMA-directed therapies, SpringWorks is conducting a global Phase 3, double-blind, randomized, placebo-controlled clinical trial to evaluate nirogacestat as a monotherapy in adults with progressing desmoid tumors.

06:38 EDT Greenwich LifeSciences publishes safety data from GP2 Phase IIb trial - Greenwich LifeSciences presented an abstract and poster of the final 5 year GP2 Phase IIb clinical trial safety data at the 2021 ASCO Annual Meeting. It has been previously reported that the completion of the GP2 immunotherap. Primary Immunization Series reduced recurrence rates to 0% over a 5 year follow-up period in HER2 3+ patients who had received a standard course of trastuzumab after surgery. The abstract and poster present the final safety data over the 5 year follow-up period, assessing the safety of GP2 immunotherapy and its relationship to previously presented peak immunity and recurrence rate data. Summary of the Final 5 Year Safety Data: GP2 immunotherapy is well-tolerated and no safety signal for GP2 was identified. Additionally, no serious adverse events related to GP2 immunotherapy were reported over the full 5 year treatment and follow-up periods. The majority of patients experienced mild or moderate injection site reactions, which accounted for approximately 70% of reported adverse events. The incidence of adverse events was similar across HER2 3+ and HER2 1-2+ breast cancer patients, consistent with the previously reported findings that the immune response was similar across both patient populations, suggesting that GP2 immunotherapy could be a potential treatment in HER2 1-2+ patients or in other HER2 expressing cancers. Excerpts from the ASCO Poster 542: Title: Final five year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer Safety data was analyzed to assess injection site reactions and systemic adverse events of each treatment arm. Most patients completed the planned PIS: 81 GP2+GM-CSF and 86 GM-CSF only. In addition, 77 GP2+GM-CSF and 80 GM-CSF only patients received all 4 booster injections. The most common injection site reactions were erythema, induration and pruritis, and they occurred with similar frequency in the two treatment arms. Injection site reactions were reported by almost all patients over the course of vaccinations. Occurring in a smaller percentage of patients, the most common systemic adverse events were fatigue, headache, and myalgia/arthralgia, again with similar incidence by treatment arm. The majority of all events reported were of grade 1, mild severity. Five GP2+GM-CSF patients reported 6 events considered definitely, possibly or probably related to study medication, which were grade 3 or 4: induration (2), urticaria, rash, pruritis, and arthralgia. Urticaria, allergic reaction and hypersensitivity reaction were considered possibly related events of grade 3 or 4 in GM-CSF only patients. No serious adverse events considered related to study medication were reported over the full 5 year treatment and follow-up periods. Figure 2 of the poster shows the maximal severity grade for any adverse event, systemic and injection site reaction, for each patient. There was no difference between the two treatment arms. The majority of events were of grade 1, mild severity. Two patients reported grade 4 adverse events deemed unrelated to GP2 immunotherapy. One GP2+GM-CSF patient experienced grade 4 hypoglycemia and recovered. A GM-CSF only patient was diagnosed with renal cell carcinoma, a second primary diagnosis, which was classified as grade 4. Tables 1 & 2 of the poster show the incidence of adverse events by HER2 status. The first occurrence of frequently reported adverse events are tabulated in Table 1. The most common adverse event was injection site reaction. Almost every patient, in both the GP2+GM-CSF and GM-CSF only arms, reported injection site reactions. The most frequent injection site reactions were erythema, pruritus and induration, as presented in Table 2. The incidence of adverse events were similar across HER2 3+ and HER2 1-2+ patients, which is consistent with the previously reported findings that immune response was similar across HER2 3+ and HER2 1-2+ patients.

06:35 EDT Lion Electric names Francois Beaulieu as chief information officer - Lion Electric announced that it has named Francois Beaulieu as chief information officer, or CIO, effective immediately. In his new role, Beaulieu will guide Lion's digital initiatives and will be tasked with optimizing the company's investments in the information technologies that underpin its organizational processes. Since 2011, Beaulieu has worked in a variety of consulting capacities, managing major digital infrastructure transitions and optimizing back-office platforms for clients. Most recently he served as a strategic technology advisor for Efico's CIO on Demand service.

06:32 EDT Ault Global Holdings to make additional investment in Ault Alliance - Ault Global Holdings announced the Company anticipates making an additional investment in Ault Alliance, its wholly-owned subsidiary, to expand the infrastructure of its technology data center in southern Michigan and increase the power capacity to 28MW. The Company's decision to accelerate the timing of its investment in the technology data center was driven by an increase in demand for high-density computing due to improved business conditions for cryptocurrency mining, including the market prices of digital currencies. By dedicating the increased power capacity for high-density computing, which requires a significantly smaller footprint, the Company anticipates that this investment will allow the Company to reduce the timeline to reach its revenue projections. At 50% capacity, the technology data center is expected to generate annual gross revenues between $54M and $64M. The technology data center power capacity can be further expanded in the future, up to 300MW. The technology data center features cloud, high-density, and enterprise data center services and is operated by Alliance Cloud Services, a subsidiary of Ault Alliance/

06:22 EDT Spirit AeroSystems enters exclusive agreement with Rolls-Royce for nacelles - Spirit AeroSystems (SPR) has entered into an exclusive agreement with Rolls-Royce (RYCEY) to design and build the next generation of slim-line nacelles for the company's newest engine, the Pearl 10X. The company's brand new, ready-for-assembly ultra-slim nacelle improves laminar flow to improve aircraft performance and acoustic impedance. For production, Spirit will leverage its composite and fabrication capabilities at its Wichita facility to support the program. Spirit will provide competitive aerostructures with kits that Rolls-Royce can seamlessly install during final assembly, helping to speed up processes. .

06:12 EDT United Therapeutics seeks trade secret misappropriation claims against Liquidia - United Therapeutics (UTHR) announced that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, a subsidiary of Liquidia (LQDA) and a former United Therapeutics employee who later joined Liquidia as an executive. The claims allege that Liquidia conspired with the former employee to misappropriate United Therapeutics' trade secrets, including regulatory submissions and detailed financial forecasts, in the development of Liquidia's product, LIQ861. United Therapeutics initially filed a patent infringement lawsuit in June 2020 in response to a new drug application, or NDA, filed by Liquidia with the FDA requesting approval to market LIQ861, a dry powder inhalation formulation of treprostinil. The NDA was filed under the 505 regulatory pathway with United Therapeutics' product, Tyvaso Inhalation Solution, as the reference listed drug. In April 2020, United Therapeutics received a Paragraph IV notification letter from Liquidia indicating that Liquidia's NDA contains a certification alleging that LIQ861 will not infringe any of the patents then listed in the Orange Book for Tyvaso because those patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use, or sale of LIQ861. In response, United Therapeutics sued Liquidia for infringing two patents, U.S. Patent Nos. 9,604,901 and 9,593,066, and later added a third patent, U.S. Patent No. 10,716,793, in the United States District Court for the District of Delaware. As a result of United Therapeutics' lawsuit, FDA is precluded from approving LIQ861 until the expiration of a 30-month stay in October 2022, or the entry of final judgment in the litigation, whichever comes first. During discovery in the patent infringement case, United Therapeutics uncovered evidence that a former United Therapeutics employee took United Therapeutics' trade secrets when he left the company and joined Liquidia to develop LIQ861. The former employee, who was central to Tyvaso's development, brought to Liquidia confidential United Therapeutics documents, including confidential FDA submissions and detailed financial forecasts relating to Tyvaso. On June 4, United Therapeutics filed a motion alleging that Liquidia used these trade secrets in the development of LIQ861 and seeking permission from the court to pursue these additional claims based on this newly-discovered information. United Therapeutics is seeking monetary damages to compensate it for this misappropriation, trebled damages, punitive damages, attorneys' fees, and injunctive relief. The case is currently scheduled for trial in March 2022.

06:07 EDT Acura Pharmaceuticals announces completion of registration batches of LTX-03 - Acura Pharmaceutical announced the completion of three NDA required registration batches of the to-be-marketed LTX-03 formulation. The LTX-03 tablets were manufactured on commercial scale equipment and passed all requisite quality assurance tests. The LTX-03 tablets from these batches will be used in a six month shelf life stability study, which will commence immediately, and in human clinical studies, which will commence after an update to the Investigation New Drug application on file with the Food and Drug Administration. The company said, "We, along with our Partner, Abuse Deterrent Pharmaceuticals, LLC, intend to conduct 3 clinical studies as was proposed to the FDA in our updated IND submitted in February 2021."

06:05 EDT Datto reintroduces Virtual SIRIS data protection software - Datto Holding reintroduced its Virtual SIRIS data protection software. Delivered as a virtual appliance, this software-only version of the industry-leading Datto SIRIS solution provides MSPs with the flexibility to meet the diverse data protection requirements of their small and medium business clients with fully integrated software running on their own hardware. Designed to support private cloud and virtual deployments, vSIRIS provides MSPs with comprehensive, highly scalable software backed by the immutable Datto cloud. Built with the same leading data backup and recovery capabilities as SIRIS, MSPs can protect their clients without the need for Datto hardware. vSIRIS can be installed remotely and runs as a virtual machine in either VMware ESX or Microsoft Hyper-V. It provides the ability to dynamically add resources to support changing workloads and connects to external storage, including storage area networks and network-attached storage devices.

06:01 EDT Facebook acquires Unit 2 Games, studio behind Crayta gaming platform - Facebook announced that it is buying Unit 2 Games, which builds a platform called Crayta. "Crayta has maximized current cloud-streaming technology to make game creation more accessible and easy to use. We plan to integrate Crayta's creation toolset into Facebook Gaming's cloud platform to instantly deliver new experiences on Facebook," said Vivek Sharma, VP, Facebook Gaming. Reference Link

05:23 EDT Addex Therapeutics enrolls first patients in JNJ-40411813 study - Addex Therapeutics (ADNX) announced that the first patients have been enrolled into a Phase 2 clinical study evaluating JNJ-40411813 in patients with epilepsy. JNJ-40411813 is a selective metabotropic glutamate type 2, or mGlu2, receptor positive allosteric modulator, or PAM. The trial is being conducted in collaboration with Janssen Pharmaceuticals, part of Johnson & Johnson (JNJ).

05:11 EDT Philips, Elekta sign agreements to expand cancer care partnership - Elekta (EKTAY) and Philips (PHG) signed agreements to deepen their existing strategic partnership to advance cancer care through precision oncology solutions. The extended collaboration builds on the two companies' cooperation in the field of magnetic resonance, or MR-guided adaptive radiation therapy. Through deeper cross-portfolio collaboration, Elekta and Philips will utilize their capabilities to improve patient care. The company said, "This integrated approach has the potential to provide: Quicker, more accurate visualization of the tumor, easier decision of optimal treatment strategy, earlier assessment of therapy response, more effective and efficient therapy delivery. The strengthened strategic partnership intends to further deliver a superior experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and more precise therapy for patients, and lowered costs of care for healthcare providers. In this preferred, although non-exclusive, partnership, Elekta and Philips will leverage their capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties' systems and software in order to drive precision in oncology."